Ca Esophagus
Esophageal cancer is a malignant neoplasm of the esophageal mucosa, predominantly squamous cell carcinoma or adenocarcinoma, presenting with progressive dysphagia and weight loss.
CA Esophagus (Esophageal Carcinoma)
Esophageal carcinoma (CA esophagus) refers to a malignant neoplasm arising from the epithelium of the esophagus. The two dominant histological types are squamous cell carcinoma (SCC) and adenocarcinoma (ADC), which together account for > 95% of all esophageal malignancies [1][2].
- Esophageal → from Greek oisophagos ("oi-" = to carry, "phagos" = food) — the tube that carries food.
- Carcinoma → from Greek karkinos (crab) + -oma (tumour) — a malignant tumour of epithelial origin.
The key concept: the esophagus is a muscular tube with no serosal layer (it has an adventitia instead). This is critical because a serosal barrier normally slows tumour invasion into surrounding tissues. Without serosa, esophageal cancers tend to invade locally early and present at an advanced stage [1][2].
"Typically exhibits extensive proximal and distal submucosal invasion" [1] — tumour can spread longitudinally within the submucosa well beyond the visible macroscopic margin, which is why surgical resection margins need to be generous (≥ 5 cm proximally and distally).
2. Epidemiology
| Feature | Detail |
|---|---|
| Global rank | 6th most common cancer in the world [1]; 6th leading cause of cancer death worldwide |
| Sex | Male preponderance (M:F ≈ 3:1) [2] |
| Age | Disease of mid to late adulthood — peak incidence 60–70 years [1][2] |
| HK histology | SCC is most common in Asians including HK (≈ 90%) [2]; adenocarcinoma is increasing but remains the minority |
| Western histology | Adenocarcinoma has overtaken SCC in incidence in Western countries, primarily driven by obesity and GERD |
| Prognosis | Poor: > 50% have metastatic disease at presentation; 5-year overall survival is just 5–10% [2] |
Why is prognosis so poor?
Three reasons: (1) no serosa → early transmural invasion, (2) rich submucosal lymphatic plexus → early lymphatic spread, (3) late presentation — dysphagia only appears when ≥ 60–75% of the lumen is obstructed.
- "Asian esophageal cancer belt": stretches from Northern China through Central Asia to the Caspian coast of Iran — extremely high incidence of SCC, linked to dietary nitrosamines, hot beverages, and nutritional deficiencies.
- In Hong Kong: SCC dominates — closely related to smoking, alcohol, hot drinks, nitrosamines, betel nut [2].
- In the West: ADC is rising — closely linked to the obesity epidemic, GERD, and Barrett's esophagus.
3. Anatomy and Function of the Esophagus
Understanding esophageal anatomy is essential because tumour location determines symptoms, spread pattern, operability, and surgical approach.
| Feature | Detail |
|---|---|
| Length | ~25 cm in adults (from cricopharyngeus C6 to esophagogastric junction T11) |
| Divisions | Cervical (C6–thoracic inlet), Upper thoracic (thoracic inlet–carina), Middle thoracic (carina–halfway to EGJ), Lower thoracic/abdominal (halfway–EGJ) |
| Clinically | Upper 1/3 (~15–24 cm from incisors), Middle 1/3 (~24–32 cm), Lower 1/3 (~32–40 cm) |
- Mucosa — non-keratinising stratified squamous epithelium (except at the gastroesophageal junction where it transitions to columnar — the "Z-line")
- Submucosa — contains the submucosal (Meissner's) plexus which controls secretory activity; also contains a dense lymphatic network (clinically important — tumour spreads submucosally via this plexus) [1]
- Muscularis propria — inner circular + outer longitudinal muscle layers; contains the myenteric (Auerbach's) plexus which controls motility [1]
- Upper 1/3: striated muscle
- Middle 1/3: mixed striated + smooth muscle
- Lower 1/3: smooth muscle
- Adventitia — NO SEROSA — only loose connective tissue blending with mediastinal structures
Why does the absence of serosa matter?
Students commonly underestimate this point. The serosa is a mesothelial barrier that delays transmural invasion in gastric and colonic cancers. The esophagus has only adventitia → tumour penetrates into surrounding mediastinal structures (trachea, aorta, pericardium) far earlier and more easily. This is also why T3 esophageal cancer means invasion of adventitia (not serosa).
These are sites of physiological constriction where food (and swallowed foreign bodies) can get stuck — and where SCC tends to arise:
- Cricopharyngeus (~15 cm from incisors) — upper esophageal sphincter
- Aortic arch / Left main bronchus (~23–25 cm from incisors) — extrinsic compression
- Diaphragmatic hiatus / Lower esophageal sphincter (~38–40 cm from incisors)
| Region | Arterial Supply | Venous Drainage | Lymphatic Drainage |
|---|---|---|---|
| Upper 1/3 | Inferior thyroid artery | Brachiocephalic vein | Deep cervical nodes |
| Middle 1/3 | Aorta (esophageal branches) | Azygos vein | Superior and posterior mediastinal nodes |
| Lower 1/3 | Left gastric artery (esophageal branches) | Left gastric vein (→ portal vein) | Celiac nodes and nodes along left gastric vessels |
Why does this matter clinically?
- Lymphatic drainage is longitudinal and bidirectional — cancer at any level can spread to nodes far from the primary site, making "skip metastases" common.
- The lower 1/3 drains into the portal system — this is why hepatic metastases are common in lower esophageal/EGJ tumours.
- Posteriorly: thoracic vertebral bodies, thoracic duct, azygos vein, descending aorta
- Anteriorly: trachea (upper), left main bronchus (mid), pericardium and left atrium (lower)
- Left: aortic arch, thoracic duct (crosses from right to left at ~T5), left recurrent laryngeal nerve (loops under aortic arch)
- Right: azygos vein
These relationships explain patterns of local invasion:
Tumours at the EGJ are particularly important to classify because it determines whether they are staged/treated as esophageal or gastric cancers:
Siewert classification [1]:
- Type I = Located 1–5 cm proximal to the anatomical Z-line → adenocarcinoma of the distal esophagus, usually arising from Barrett's esophagus
- Treatment: Transthoracic en bloc esophagectomy + partial gastrectomy + 2-field lymphadenectomy
- Type II = Located 1 cm proximal to 2 cm distal to Z-line → true carcinoma of the cardia
- Treatment: Transabdominal/transhiatal resection of distal esophagus + total gastrectomy + lymphadenectomy of lower mediastinum and abdominal D2 nodal compartment
- Type III = Located 2–5 cm distal to Z-line → subcardial gastric carcinoma infiltrating EGJ from below
- Treatment: same as Type II
Per AJCC 8th edition: Siewert I and II are staged as esophageal cancer; Siewert III and cardia cancers not involving EGJ are staged as stomach cancer [1].
4. Etiology and Risk Factors
The two histological types have distinct risk factor profiles — think of them as almost separate diseases sharing the same organ.
SCC arises from the native squamous epithelium. It is multicentric [1] (consistent with the "field cancerization" concept — the entire aerodigestive mucosa is bathed in carcinogens).
| Risk Factor | Mechanism / Explanation |
|---|---|
| Smoking [1][2][3] | Polycyclic aromatic hydrocarbons (PAHs) and nitrosamines cause direct mucosal DNA damage; synergistic with alcohol |
| Alcohol [1][2][3] | Ethanol → acetaldehyde (a class 1 carcinogen via IARC); damages mucosal DNA; acts as a solvent enhancing penetration of other carcinogens (synergism with smoking) |
| Hot drinks [2] | Thermal injury → chronic inflammation → epithelial hyperplasia → dysplasia → carcinoma (common in Asian/Middle Eastern tea-drinking cultures) |
| Nitrosamines [2] | Potent environmental carcinogens found in preserved/pickled foods |
| Dietary factors [1] | Restricted diet of salted fish and pickled vegetables, deficiency of vegetables and citrus fruit, deficiency of trace elements (e.g., selenium), fungal contaminants (e.g., aflatoxin) |
| Betel nut [2][3] | Contains arecoline → genotoxic; common in South/Southeast Asian populations |
| Corrosive/caustic strictures [1] | Chronic inflammation at stricture site → epithelial regeneration → increased mitotic rate → accumulated mutations → SCC (latency period can be 30–40 years) |
| Achalasia [1] | Stasis of food in dilated esophagus → chronic mucosal irritation and bacterial overgrowth → nitrosamine production → SCC |
| Plummer-Vinson syndrome (PVS) [2] | Triad of post-cricoid dysphagia, iron deficiency anemia (IDA), esophageal web — unknown exact pathophysiology but web formation causes chronic mucosal changes → SCC |
| Tylosis [2] | Autosomal dominant genetic disorder characterised by hyperkeratosis of palms & soles + oral leukoplakia — nearly 100% lifetime risk of esophageal SCC (mutation in RHBDF2 gene) |
| History of H&N cancer [1] | Field cancerization — same carcinogens (smoking/alcohol) affect the entire aerodigestive tract → high risk of synchronous (within 6 months) and metachronous ( > 6 months) tumours [1] |
| Prior radiation [1] | Radiation for H&N tumours → direct DNA damage to esophageal epithelium |
Field Cancerization — A Must-Know Concept
Diffuse and chronic exposure of mucosa of the upper aerodigestive tract to carcinogenic substances leads to widespread epithelial changes [1]. This is why:
- Patients with oral cavity/oropharyngeal tumours are more likely to develop a second primary in the upper esophagus [1]
- Patients with laryngeal tumours are more likely to develop a second primary in the lung [1]
- Panendoscopy (direct laryngoscopy + bronchoscopy + OGD) is always recommended at the initial evaluation of all patients with primary cancers of the upper aerodigestive tract [1]
ADC arises from metaplastic columnar epithelium (Barrett's esophagus) or from the cardia. It is not multicentric [1] — it arises from a single focus of intestinal metaplasia.
| Risk Factor | Mechanism / Explanation |
|---|---|
| Smoking [1] | Direct carcinogenic effect on esophageal mucosa |
| Obesity [1] | ↑ Intra-abdominal pressure → ↑ GERD → Barrett's → ADC; also promotes a pro-inflammatory state (↑ leptin, ↓ adiponectin, ↑ insulin/IGF-1) that promotes carcinogenesis |
| GERD [1][2] | Chronic acid + bile reflux → inflammation → erosive esophagitis → intestinal metaplasia (Barrett's) → low-grade dysplasia → high-grade dysplasia → invasive adenocarcinoma (the "metaplasia-dysplasia-carcinoma" sequence) |
| Barrett's esophagus [1][2] | Metaplastic columnar epithelium (with goblet cells) that replaces stratified squamous epithelium in the distal esophagus — this is the pre-malignant lesion; risk of ADC is ~0.5% per year [2] |
| Hiatus hernia | Disrupts the anti-reflux mechanism → promotes GERD → Barrett's |
| Male sex, Caucasian | Epidemiological association (ADC is more common in white males) |
The Barrett's → Adenocarcinoma Sequence (Detailed)
This is the classic metaplasia → dysplasia → carcinoma sequence:
Why does intestinal metaplasia occur? The esophageal squamous epithelium is not built to handle acid. Under chronic acid exposure, stem cells in the basal layer differentiate into columnar (intestinal-type) epithelium with goblet cells — an adaptation that is more resistant to acid, but this metaplastic tissue is inherently unstable and prone to dysplastic change [1][2].
Barrett's esophagus definition: intestinal metaplasia of esophageal stratified squamous epithelium to columnar epithelium (with mucus-secreting goblet cells) as an adaptation mechanism to long-term acid reflux [2]
5. Pathophysiology
| Feature | SCC | ADC |
|---|---|---|
| Site | Mostly upper 2/3 | Mostly lower 1/3 |
| Precursor | Squamous dysplasia | Barrett's metaplasia → dysplasia |
| Morphology | Fungating > ulcerative > infiltrative [2] | Fungating or ulcerating mass |
| Multicentricity | Multicentric (field cancerization) [1] | Not multicentric [1] |
| Sensitivity to chemoRT | More sensitive to chemoRT [2] | Less sensitive to chemoRT → surgery preferred [2] |
| Molecular drivers | p53 mutations, EGFR amplification, cyclin D1 overexpression | p53 mutations, HER2 amplification (targetable), VEGF |
Other possible pathology (rare): neuroendocrine tumour, leiomyoma, GIST, lymphoma [2]
5.2 Modes of Spread [1][2]
Understanding the modes of spread is essential for staging and determining resectability:
- Direct extension (e.g., tracheoesophageal fistula) [1][2]
- The esophagus has no serosa → tumour easily invades adjacent structures:
- Trachea / left main bronchus → TE fistula (cough on swallowing, recurrent aspiration pneumonia)
- Aorta → aortoesophageal fistula (massive, usually fatal hemorrhage)
- Pericardium / left atrium → pericardial effusion, cardiac tamponade
- Recurrent laryngeal nerve (RLN) → vocal cord paralysis → hoarseness
- Thoracic duct → chylothorax
- Diaphragm, pleura → pleural effusion
- Vascular and lymphatic spread [2]
- The submucosal lymphatic plexus is the highway for early spread — tumour cells can travel longitudinally for centimetres within the submucosa before penetrating the wall
- Lymphatic drainage is bidirectional (upward and downward) → "skip metastases" are common (nodes far from the primary can be involved)
- Important nodal groups:
- Cervical: deep cervical, supraclavicular (Virchow's node — left supraclavicular, classically associated with abdominal malignancy but also seen in lower esophageal/EGJ tumours)
- Mediastinal: paraesophageal, subcarinal, paratracheal
- Abdominal: celiac, left gastric, common hepatic
- Metastasis to organs including: lungs, liver, bones, adrenals [1]
- Lower esophageal tumours drain via the left gastric vein → portal system → liver metastases
- Upper/middle tumours drain via brachiocephalic/azygos → lung metastases
- Bony and adrenal metastases via systemic circulation
"Typically exhibits extensive proximal and distal submucosal invasion" [1]. The longitudinal submucosal lymphatic plexus allows tumour to spread far beyond the visible mucosal lesion. This is why:
- Frozen section of resection margins is performed intra-operatively
- A proximal margin of at least 5 cm (some centres use 8 cm) is recommended
- Multifocal submucosal deposits ("satellite nodules") may be found
6. Classification
| Type | Frequency | Site | Origin |
|---|---|---|---|
| Squamous cell carcinoma | ~90% in HK/Asia | Upper 2/3 | Squamous epithelium |
| Adenocarcinoma | ~10% in HK (rising); dominant in West | Lower 1/3 / EGJ | Barrett's metaplasia |
| Other (rare) | < 5% | Any | Neuroendocrine tumour, leiomyoma, GIST, lymphoma, melanoma, small cell carcinoma |
| Region | Distance from incisors | Anatomical Landmarks |
|---|---|---|
| Cervical esophagus | 15–20 cm | Cricopharyngeus to thoracic inlet (sternal notch) |
| Upper thoracic | 20–25 cm | Thoracic inlet to lower border of azygos vein |
| Middle thoracic | 25–30 cm | Lower border of azygos vein to lower border of inferior pulmonary vein |
| Lower thoracic | 30–40 cm | Lower border of inferior pulmonary vein to EGJ (includes abdominal segment) |
6.3 TNM Staging (AJCC 8th Edition) [1]
| Stage | Description |
|---|---|
| TX | Primary tumour cannot be assessed |
| T0 | No evidence of primary tumour |
| Tis | High-grade dysplasia (includes all non-invasive neoplasia — previously called "carcinoma in situ") |
| T1a | Tumour invades lamina propria or muscularis mucosae |
| T1b | Tumour invades submucosa |
| T2 | Tumour invades muscularis propria |
| T3 | Tumour invades adventitia (remember: no serosa!) |
| T4a | Resectable tumour invading pleura, pericardium, or diaphragm |
| T4b | Unresectable tumour invading other adjacent structures (aorta, vertebral body, trachea) |
T4a vs T4b
This distinction is critical for surgical planning. T4a is resectable (pleura, pericardium, diaphragm can be resected en bloc). T4b is unresectable (aorta, vertebral body, trachea — you cannot safely remove these structures). Students commonly confuse this boundary.
| Stage | Description |
|---|---|
| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | 1–2 regional lymph nodes involved |
| N2 | 3–6 regional lymph nodes involved |
| N3 | ≥ 7 regional lymph nodes involved |
| Stage | Description |
|---|---|
| M0 | No distant metastasis |
| M1 | Distant metastasis present |
6.4 Siewert Classification (for EGJ tumours) — see Section 3.6 above
- Fungating > ulcerative > infiltrative — fungating (polypoid/exophytic) is most common
- Infiltrative (linitis plastica-type) has the worst prognosis as it often causes extensive submucosal spread without a clear mass
7. Clinical Features
Esophageal cancer is typically a "silent" cancer until it reaches an advanced stage. The esophageal lumen must be narrowed to ≤ 13 mm (normal ~20 mm) before solid food dysphagia occurs, meaning ≈60–75% of the lumen is already obstructed by the time patients present. This is the core reason for the late presentation and poor prognosis.
7.1 Symptoms
| Symptom | Pathophysiological Basis |
|---|---|
| Dysphagia [1] — first and most common manifestation | Progressive mechanical obstruction of the esophageal lumen. Initially for solids (the lumen can still accommodate liquids), then progresses to semi-solids, then liquids ("progressive dysphagia for solids > liquids" — the hallmark of mechanical obstruction). Patients tolerate fluid and soft food better [1]. |
| Odynophagia [1] — develops late in disease course, usually due to extra-esophageal involvement | Pain on swallowing indicates ulceration of the tumour surface ± invasion into periesophageal tissues (mediastinal inflammation). When extra-esophageal involvement occurs (e.g., mediastinal invasion), the pain becomes more severe and constant. |
| Regurgitation (reflux) [1] — secondary to tumour disrupting normal peristalsis | Tumour mass and/or submucosal infiltration disrupts the peristaltic wave → food pools above the tumour → regurgitates back up. This carries a risk of aspiration pneumonia [1]. |
| Hematemesis or melena [1] | Rare manifestation, usually occurs late. Bleeding from primary tumour or erosion into aorta or pulmonary vessels [1]. Mucosal ulceration → chronic low-grade bleeding → IDA; erosion into aorta → catastrophic hemorrhage. |
| Symptom | Pathophysiological Basis |
|---|---|
| Anorexia and weight loss [1] | Multifactorial: (1) mechanical obstruction → reduced oral intake, (2) cancer-induced cachexia (pro-inflammatory cytokines: TNF-α, IL-6 → increased basal metabolic rate + muscle wasting), (3) dysphagia → nutritional deficiency |
| Anemic symptoms [1]: pallor, palpitations, dyspnea, fatigue | Chronic occult blood loss from ulcerated tumour → iron deficiency anemia |
| Nausea and vomiting [1] | Obstruction + altered motility; also as a component of cancer cachexia |
These indicate the tumour has invaded beyond the esophageal wall into surrounding structures:
| Symptom | Structure Invaded | Pathophysiological Basis |
|---|---|---|
| Hoarseness [1] | Recurrent laryngeal nerve (RLN) | The left RLN loops under the aortic arch and ascends in the tracheoesophageal groove → vulnerable to invasion by mid-esophageal and upper thoracic tumours. Paralysis of the ipsilateral vocal cord → breathy hoarseness. |
| Persistent cough / aspiration pneumonia | Tracheobronchial tree | Direct invasion → tracheoesophageal fistula [1][2] → ingested food/liquid enters the airway → cough triggered by swallowing (pathognomonic), recurrent pneumonia |
| Coughing on swallowing (Ono's sign) | TE fistula | Fistula between esophagus and trachea/bronchus → immediate cough reflex when swallowing liquids |
| Chest/back pain | Mediastinal invasion | Invasion into periesophageal tissue, vertebral bodies, or nerves → somatic/neuropathic pain |
| Dyspnea | Tracheobronchial compression or invasion | Mass effect or direct invasion narrowing the airway; also pleural effusion from pleural metastases |
| Superior vena cava (SVC) syndrome | SVC compression | Large mediastinal mass or nodal disease compressing the SVC → facial/upper limb oedema, distended neck veins, headache |
| Horner's syndrome | Cervical sympathetic chain | Invasion of the sympathetic trunk → ipsilateral ptosis, miosis, anhidrosis |
| Symptom | Site of Metastasis |
|---|---|
| Lymphadenopathy [1] — enlarged supraclavicular LN indicates disseminated disease | Supraclavicular (Virchow's node, especially left) |
| Hepatomegaly, jaundice, ascites | Liver metastases |
| Bone pain, pathological fractures | Bone metastases |
| Cough, hemoptysis | Lung metastases |
7.2 Signs
| Sign | Pathophysiological Basis |
|---|---|
| Cachexia (temporal wasting, loose skin folds, muscle wasting) | Cancer cachexia + reduced oral intake from dysphagia |
| Pallor | Iron deficiency anemia from chronic occult GI blood loss |
| Dehydration | Severe dysphagia → inability to maintain adequate fluid intake |
| Lymphadenopathy — supraclavicular (Virchow's node) | Left supraclavicular node drains the thoracic duct → receives lymph from the abdomen and thorax; enlarged supraclavicular LN indicates disseminated disease [1] |
| Sign | Significance |
|---|---|
| Epigastric mass (rare) | Large tumour at the EGJ palpable per abdomen |
| Hepatomegaly (irregular, hard, non-tender) | Liver metastases |
| Ascites | Peritoneal carcinomatosis |
| Sign | Basis |
|---|---|
| Hoarse voice (on speaking) | RLN palsy from tumour invasion |
| Stridor | Tracheobronchial compression/invasion |
| Horner's syndrome | Cervical sympathetic chain invasion |
| Pleural effusion (dullness to percussion, reduced breath sounds) | Pleural metastases or direct invasion |
| Pericardial effusion / tamponade (muffled heart sounds, raised JVP, hypotension — Beck's triad) | Pericardial invasion |
Exam Pearl: Triade Diagnostique of Esophageal Cancer
The classic presentation = progressive dysphagia for solids → liquids + weight loss + elderly male smoker/drinker. If there is also hoarseness, think of RLN invasion (locally advanced / unresectable disease — critical for staging).
8. Related Conditions and Their Relevance
As the precursor of esophageal ADC, Barrett's deserves special mention:
- Definition: metaplastic columnar epithelium (with mucus-secreting goblet cells) replacing squamous epithelium in the distal esophagus [2]
- Male predominance (M:F = 2:1), mean age of diagnosis = 55 years [1]
- Risk factors: obesity, hiatus hernia, erosive esophagitis, chronic GERD [1]
- Classification: Classic (≥ 3 cm) vs Short-segment ( < 3 cm) [2]
- Prague classification: C = circumferential extent, M = maximal extent [2]
- Investigations: OGD with biopsy ± chromoendoscopy (e.g., NBI, Lugol's iodine); "Seattle protocol" — biopsy every 1–2 cm in 4 quadrants [2]
- Surveillance [2]:
- No dysplasia: OGD + biopsy every 3 years ( > 3 cm) or every 5 years ( < 3 cm)
- Low-grade dysplasia: OGD at 6 months × 2 then annually if negative, or endoscopic treatment
- High-grade dysplasia: intense surveillance (every 3 months) or endoscopic treatment (e.g., EMR) — advised
- Increases risk of SCC (not ADC!) due to food stasis → chronic mucosal irritation → bacterial fermentation → nitrosamine production
- Risk of esophageal SCC in achalasia is ~3% over a lifetime; surveillance OGD is debated
- Alkali ingestion → liquefaction necrosis → transmural damage → stricture formation over years
- Acid ingestion → coagulative necrosis with eschar → limited penetration but damage to stomach (pooling in antrum due to pylorospasm)
- The latency period from caustic injury to SCC development can be 30–40 years
- Surveillance OGD should begin 15–20 years after caustic ingestion
- Triad: post-cricoid dysphagia + iron deficiency anemia + esophageal web
- Unknown pathophysiology
- Associated with increased risk of SCC in the post-cricoid/upper esophageal region
While not "CA esophagus," the neonatal surgery lecture slide mentions congenital esophageal conditions. Patients with repaired EA/TEF have a long-term increased risk of esophageal malignancy (both SCC and ADC) due to chronic GERD, Barrett's metaplasia, and anastomotic strictures requiring long-term endoscopic surveillance [4].
Given the lecture slides on dysphonia, laryngeal cancer, and upper airway obstruction:
- Esophageal SCC and laryngeal SCC share the same risk factors (smoking, alcohol) and the concept of field cancerization applies [1][3]
- Hoarseness in a patient with esophageal cancer should raise suspicion for either:
- RLN invasion by esophageal tumour, OR
- Synchronous laryngeal primary (field cancerization)
- Panendoscopy (direct laryngoscopy + bronchoscopy + OGD) is always recommended at initial evaluation [1]
- Upper airway obstruction can complicate locally advanced esophageal cancer (especially cervical esophageal tumours) → may require tracheostomy [3]
High Yield Summary
Definition: Malignant epithelial neoplasm of the esophagus; two main types: SCC (upper 2/3, dominant in Asia/HK ~90%) and ADC (lower 1/3, dominant in West, arising from Barrett's esophagus).
Epidemiology: Male > Female (3:1); peak age 60–70; poor prognosis (5-year survival 5–10%); > 50% have metastases at presentation.
Anatomy: 25 cm tube, no serosa (adventitia only) → early local invasion; rich submucosal lymphatic plexus → early and extensive longitudinal lymphatic spread; 3 anatomical narrowings; drainage varies by region (upper → cervical nodes; middle → mediastinal; lower → celiac/portal).
Risk factors — SCC: Smoking, alcohol, hot drinks, nitrosamines, dietary deficiency (selenium, fruit/veg), betel nut, achalasia, caustic stricture, Plummer-Vinson syndrome, tylosis, H&N cancer history (field cancerization), prior radiation.
Risk factors — ADC: GERD → Barrett's esophagus (metaplasia-dysplasia-carcinoma sequence), obesity, smoking.
Modes of spread: (1) Direct — TE fistula, RLN invasion, aortic invasion; (2) Lymphatic — bidirectional, skip metastases, Virchow's node; (3) Hematogenous — liver, lung, bone, adrenals.
Clinical features: Progressive dysphagia (solids → liquids) + weight loss = classic presentation; late features: odynophagia, hoarseness (RLN), TE fistula (cough on swallowing), hematemesis, supraclavicular lymphadenopathy.
Classifications: Histological (SCC vs ADC); Anatomical (cervical/upper/mid/lower thoracic); TNM (AJCC 8th ed); Siewert (I/II/III for EGJ tumours); Prague (Barrett's).
Field cancerization: Shared carcinogen exposure across upper aerodigestive tract → synchronous/metachronous tumours → always perform panendoscopy.
Active Recall - CA Esophagus: Definition, Epidemiology, Anatomy, Etiology, Pathophysiology, Classification, Clinical Features
[1] Senior notes: felixlai.md (Esophageal cancer, Barrett's esophagus, Achalasia, Head and neck cancer, Laryngeal carcinoma sections) [2] Senior notes: maxim.md (CA esophagus, Barrett's oesophagus, GERD, Corrosive esophagitis sections) [3] Lecture slides: GC 216. Dysphonia Laryngitis, voice abuse, tumour and laryngeal cancer.pdf; GC 219. Infections and tumours in pharynx and oral cavity.pdf; GC 220. Upper airway obstruction and tracheostomy.pdf [4] Lecture slides: Neonatal Surgery.pdf [5] Lecture slides: GC 189. I can't swallow oesophageal cancer.pdf
Differential Diagnosis of CA Esophagus
The differential diagnosis of esophageal carcinoma is really the differential diagnosis of its cardinal presenting symptom — progressive dysphagia — plus its secondary features (odynophagia, weight loss, UGIB, hoarseness). When a patient walks in with difficulty swallowing, your job is to systematically work through the possibilities before landing on malignancy.
The clinical thinking starts from first principles: dysphagia means something is wrong with the passage of food from the pharynx to the stomach. The problem is either structural (something physically blocking the lumen or compressing it from outside) or functional (the motility machinery is broken, but there's no physical obstruction). Let's build this out.
The Golden Rule of Dysphagia
Painless progressive dysphagia (over weeks) is malignancy until proven otherwise [2]. This is the single most important triage principle. Progressive means the dysphagia worsens over time — solids first, then semi-solids, then liquids — reflecting a growing mass that progressively narrows the lumen. Functional causes (e.g., achalasia) classically affect both solids AND liquids from the outset because the problem is motility, not a physical blockage.
Detailed Differential Diagnosis
A. Structural / Mechanical Causes (Solids > Liquids, Progressive)
These mimic CA esophagus because they produce progressive dysphagia predominantly for solids. The key to distinguishing them lies in the history, risk factors, and endoscopic/radiological findings.
| Condition | Key Distinguishing Features | Why It Mimics CA Esophagus | How to Differentiate |
|---|---|---|---|
| CA esophagus (SCC or ADC) [1][2] | Progressive dysphagia for solids → liquids; weight loss; elderly male smoker/drinker; risk factors for SCC or ADC | — This is the diagnosis you're trying to confirm or exclude | OGD + biopsy — the gold standard; gives histological diagnosis |
| Peptic stricture (from chronic GERD / reflux esophagitis) [1][6] | Long history of heartburn and acid regurgitation predating the dysphagia; dysphagia is for solids, usually slowly progressive over months to years; responds to dilatation; benign stricture on OGD (smooth, concentric narrowing at the lower esophagus) | Progressive solid dysphagia in the distal esophagus — same location as ADC | OGD: smooth, concentric narrowing without mucosal mass; biopsy shows fibrosis, no malignant cells; long GERD history |
| Esophageal webs / rings [2] | Webs = thin mucosal folds in the upper/mid esophagus (associated with Plummer-Vinson syndrome: triad of post-cricoid dysphagia, IDA, esophageal web [2]); Schatzki ring = mucosal ring at the squamocolumnar junction (lower esophagus); dysphagia is typically intermittent (especially for solid boluses like bread/meat), not relentlessly progressive | Solid food dysphagia at a fixed location | OGD or barium swallow: thin, shelf-like projection; intermittent rather than progressive pattern; no mass |
| Esophagitis (various aetiologies) [1][6] | Erosive esophagitis from GERD: heartburn history; Infective esophagitis (Candida, HSV, CMV): typically in immunocompromised patients (HIV, transplant, chemotherapy); Pill esophagitis: history of taking bisphosphonates, doxycycline, KCl, NSAIDs with minimal water | Odynophagia ± dysphagia, may cause stricture | OGD: characteristic ulcers (Candida = white plaques; HSV = discrete shallow ulcers; pill = discrete deep ulcer at level of aortic arch); biopsy + culture; drug history |
| Eosinophilic esophagitis (EoE) | Young male with history of atopy (asthma, eczema, allergic rhinitis); intermittent dysphagia and food impaction; "trachealization" of esophagus on OGD (concentric rings, linear furrows, white exudates) | Dysphagia in a younger patient, can be progressive | OGD: "ringed esophagus" appearance; biopsy: ≥ 15 eosinophils per high-power field; atopic history; responds to topical steroids/PPI |
| Corrosive / caustic stricture [2] | History of caustic ingestion (alkali or acid); stricture develops months to years later; alkali causes liquefaction necrosis with transmural damage; acid causes coagulative necrosis with eschar [2] | Long, tight stricture causing progressive dysphagia; also carries a risk of developing SCC (latency 30–40 years) | Clear history of caustic ingestion; OGD: long, irregular stricture; biopsy to exclude malignancy |
| Other esophageal malignancies (rare) [2] | Neuroendocrine tumour, leiomyoma, GIST, lymphoma | Mass lesion causing progressive dysphagia | OGD + biopsy ± EUS: submucosal mass with intact overlying mucosa (GIST, leiomyoma) vs mucosal mass; IHC for CD117/c-KIT (GIST) [7] |
GIST vs CA Esophagus on OGD
A GIST or leiomyoma arises from the muscularis propria (the muscle wall) and grows outward (exophytic) or inward (endophytic) as a smooth, rounded submucosal bulge with intact overlying mucosa. In contrast, carcinoma arises from the mucosa and appears as an irregular, ulcerated, friable mass. This distinction on OGD is a big clue [7].
| Condition | Key Features | How to Differentiate |
|---|---|---|
| Foreign body [2] | Acute onset dysphagia (not progressive); history of ingestion event (fish bone, denture, food bolus); common in children and elderly | Acute onset, clear history; lateral neck X-ray or CT may show radio-opaque FB; OGD for removal |
These are structures outside the esophagus compressing it from the exterior. Think about what surrounds the esophagus at each level:
| Cause | Mechanism | How to Differentiate |
|---|---|---|
| Tumour / Lymph nodes (e.g., CA lung, lymphoma) [2] | Mediastinal or hilar lymphadenopathy, or a lung tumour directly compressing the esophagus | CT thorax: extrinsic mass compressing esophagus; OGD: smooth extrinsic compression with intact mucosa; biopsy of the LN/mass |
| Thyroid (retrosternal goitre) [2] | Large goitre extending into the superior mediastinum; may also cause stridor and SVC obstruction | Neck examination: palpable goitre; CT neck/thorax: retrosternal extension; thyroid function tests |
| Thymus (thymoma) [2] | Anterior mediastinal mass in a patient with or without myasthenia gravis | CT thorax: anterior mediastinal mass; anti-AChR antibodies if MG suspected |
| Thoracic aortic aneurysm [2] | Large aortic aneurysm compressing the esophagus; more common in elderly with cardiovascular risk factors | CT aortogram: aneurysmal dilatation; pulsatile mass on OGD (do NOT biopsy!) |
Functional causes produce dysphagia for both solids and liquids simultaneously from the beginning because the problem is peristaltic failure rather than a physical blockage. This is the key historical discriminator.
| Condition | Key Features | How to Differentiate from CA Esophagus |
|---|---|---|
| Achalasia [1][6] | Progressive dysphagia for both solids and liquids (~100%); regurgitation of undigested food with acidic smell (fermentation); chest pain; difficulty belching; age 35–45 (younger than typical CA); bird-beak sign on barium swallow | High-resolution esophageal manometry (HRM): elevated IRP, aperistalsis, failed LES relaxation (the triad) [6]; OGD: dilated esophagus with food residue, tight cardia that can be traversed with gentle pressure [1] |
| Pseudoachalasia [1][6] | Clinically and manometrically identical to achalasia BUT caused by malignancy at the EGJ invading the esophageal neural plexus (direct invasion) or paraneoplastic syndrome [1] | Suspect if: age > 60, rapid symptom onset ( < 6 months), marked weight loss, shouldering/heaping on barium swallow [6]; differentiate by OGD + EUS [6] — reveals tumour at the cardia |
| Diffuse esophageal spasm (DES) [1][6] | Intermittent dysphagia for solids and liquids; severe chest pain (can mimic angina); "corkscrew esophagus" on barium swallow | Esophageal manometry: premature contractions in ≥ 20% of swallows but normal LES relaxation (IRP is normal) [1][6] — this distinguishes it from achalasia |
| Jackhammer (nutcracker) esophagus [1] | Intense chest pain, dysphagia; extremely high-amplitude contractions | Esophageal manometry: distal contractile integral (DCI) > 8000 mmHg·s·cm; normal LES relaxation |
| Scleroderma (systemic sclerosis) [2] | Progressive dysphagia AND severe heartburn (GERD); Raynaud's phenomenon, sclerodactyly, skin tightening; smooth muscle atrophy and fibrosis of the esophageal wall → absent peristalsis in the distal 2/3 + incompetent LES | Clinical features of systemic sclerosis (skin, Raynaud's); manometry: absent peristalsis in distal esophagus + low/absent LES pressure (opposite of achalasia where LES pressure is HIGH) |
| Neurological causes [2] | Stroke, MND, Parkinson's disease, MS, myasthenia gravis, muscle dystrophies — typically cause oropharyngeal dysphagia (difficulty initiating swallow, nasal regurgitation, coughing/choking) rather than esophageal dysphagia | The dysphagia is oropharyngeal in nature (difficulty initiating a swallow, "food won't go down from the throat"); neurological examination findings; videofluoroscopy |
| Sjögren's syndrome [2] | Dry mouth (xerostomia) → difficulty forming and propelling bolus; dysphagia is mainly oropharyngeal | Dry eyes + dry mouth; anti-Ro/La antibodies; Schirmer's test |
Achalasia vs Pseudoachalasia — A Critical Distinction
This is an exam favourite. Both present with dysphagia for solids and liquids, regurgitation, and weight loss. Both have the same manometric triad. The red flags for pseudoachalasia are: age > 60, rapid onset of symptoms ( < 6 months), severe weight loss, and shouldering on barium swallow (suggesting an extrinsic mass). OGD + EUS is the key investigation to differentiate — it reveals the cardia tumour in pseudoachalasia [1][6].
| Condition | Why It May Be Confused with CA Esophagus | How to Differentiate |
|---|---|---|
| CA stomach (especially proximal / cardia) [8] | Siewert Type II/III tumours can present with dysphagia by obstructing the EGJ from below; constitutional symptoms overlap | OGD: tumour centered at the cardia/fundus; Siewert classification determines whether it's staged as esophageal or gastric [1]; EUS and CT for staging |
| Gastric outlet obstruction (GOO) from distal gastric cancer | Presents with vomiting, early satiety, weight loss — but not dysphagia (food enters the stomach fine, it just can't leave) | Projectile vomiting of undigested food; succussion splash; OGD: distal gastric/pyloric mass |
Since CA esophagus can present with hematemesis, melena, or IDA, the UGIB differential must be considered [5]:
| Condition | Key Features |
|---|---|
| Peptic / duodenal ulcer [5] | 4 major risk factors: H. pylori + NSAIDs + stress + excess gastric acid [5]; epigastric pain related to meals |
| Esophagogastric varices [5] | History of liver cirrhosis / portal hypertension; massive hematemesis |
| Erosive esophagitis / esophageal ulcers [5] | Long GERD history; erosive changes on OGD |
| Mallory-Weiss syndrome [5] | Forceful retching/vomiting preceding hematemesis; longitudinal mucosal tear at EGJ [5] |
| Gastritis / duodenitis [5] | Drug-induced (NSAIDs, aspirin), alcohol, stress; typically self-limited |
| Dieulafoy's lesion [5] | Aberrant submucosal vessel that erodes overlying epithelium without a primary ulcer; massive, intermittent UGIB |
| Upper GI malignancy [5] | Constitutional symptoms (weight loss, anorexia) distinguish this from benign causes |
These are the questions that help you sort through the differential at the bedside [1]:
| Question | What It Discriminates | Reasoning |
|---|---|---|
| "Do you have problems initiating a swallow or does food get stuck a few seconds after swallowing?" [1] | Oropharyngeal vs esophageal dysphagia | Initiation difficulty = oropharyngeal (neurological/muscular); food sticking = esophageal (structural/motility) |
| "Do you have problems swallowing solids, liquids, or both?" [1] | Mechanical vs motility | Inability to swallow liquid suggests a motility disorder; inability to swallow solid then progressing to liquid suggests a mechanical disorder [1] |
| "Have your symptoms progressed, remained stable, or been intermittent?" [1] | Malignancy vs benign | Rapidly progressive dysphagia suggests malignancy; intermittent dysphagia suggests primary or secondary motility disorders [1] |
| "Can you point to where food gets stuck?" [1] | Localisation | Cervical region → oropharyngeal; suprasternal notch / retrosternal → esophageal [1] |
| Associated symptoms [1] | Various | Coughing/choking/nasal regurgitation → oropharyngeal; heartburn/regurgitation → GERD; weight loss/anorexia → malignancy; hoarseness → RLN invasion (locally advanced CA); choking on swallowing → TE fistula |
| Feature | CA Esophagus | Peptic Stricture | Achalasia | Eosinophilic Esophagitis | Extrinsic Compression |
|---|---|---|---|---|---|
| Age | 60–70 | Any (long GERD hx) | 35–45 | 20–40 | Varies |
| Onset | Progressive (weeks–months) | Slowly progressive (months–years) | Progressive (months–years) | Intermittent with food impaction | Variable |
| Solids vs liquids | Solids → liquids | Solids | Solids AND liquids | Solids (food impaction) | Solids |
| Pain | Odynophagia (late) | Heartburn | Chest pain, regurgitation | Chest pain | Varies |
| Weight loss | Prominent | Mild | Mild–moderate | Mild | Varies |
| Key investigation | OGD + biopsy | OGD | Manometry | OGD + biopsy (≥ 15 eos/HPF) | CT thorax |
The reason painless progressive dysphagia is malignancy until proven otherwise [2] is a matter of urgency and consequences:
- Prognosis worsens rapidly with delay — by the time the lumen is narrowed enough to cause dysphagia, the tumour is usually T3 or beyond
- Window for curative surgery is narrow — only ~30–40% of patients are candidates for surgery at diagnosis; further delay drops this further
- All other causes are either benign or treatable without the same urgency — peptic stricture can be dilated, achalasia can be managed medically/endoscopically, webs/rings can be disrupted
Therefore the first investigation in any patient with progressive dysphagia is OGD with biopsy — this simultaneously diagnoses and excludes malignancy [2][6].
High Yield Summary — Differential Diagnosis of CA Esophagus
- Progressive dysphagia for solids → liquids = mechanical obstruction until proven otherwise → CA esophagus is the number one concern
- Solids AND liquids from onset = motility disorder (achalasia, DES, scleroderma)
- Intermittent dysphagia with food impaction in a young atopic male = eosinophilic esophagitis
- Pseudoachalasia mimics achalasia but is caused by cardia malignancy — suspect if age > 60, rapid onset, severe weight loss
- Extramural "4Ts": Tumour/LN, Thyroid, Thymus, Thoracic aortic aneurysm
- Always perform OGD + biopsy as the first-line investigation for progressive dysphagia
Active Recall - Differential Diagnosis of CA Esophagus
References
[1] Senior notes: felixlai.md (Esophageal cancer, Achalasia, Barrett's esophagus, Head and neck cancer sections) [2] Senior notes: maxim.md (CA esophagus, Dysphagia differential diagnosis, Barrett's oesophagus, Corrosive esophagitis, Zenker's diverticulum sections) [5] Senior notes: felixlai.md (UGIB differential diagnosis section); maxim.md (UGIB section) [6] Senior notes: felixlai.md (Achalasia diagnosis section, GERD section, Dysphagia history taking); maxim.md (Achalasia section, GERD section) [7] Senior notes: maxim.md (GIST section) [8] Senior notes: maxim.md (CA stomach / Siewert classification section)
Diagnostic Criteria, Algorithm, and Investigations for CA Esophagus
When a patient presents with suspected esophageal cancer (typically progressive dysphagia + weight loss in an elderly male), the diagnostic workup has three sequential goals:
- Confirm the diagnosis — histological proof of malignancy (OGD + biopsy)
- Stage the disease — determine T, N, and M (EUS, CT, PET-CT, ± laparoscopy, ± bronchoscopy)
- Assess fitness for treatment — can this patient tolerate surgery? (bloods, lung function, cardiac assessment, nutritional status)
The reason staging comes after histological confirmation is simple: there's no point doing a PET-CT on a benign peptic stricture. And the reason fitness assessment matters is that esophagectomy is one of the biggest operations in surgery — perioperative mortality is 2–5% even in high-volume centres.
There are no formal "diagnostic criteria" in the same way as, say, rheumatoid arthritis or heart failure. The diagnosis of esophageal cancer is histopathological — you need tissue.
Diagnosis: OGD + biopsy — confirmatory histological diagnosis and pre-op assessment [2]
The OGD report must document [2]:
- Proximal margin (distance from incisors) — determines anatomical location (cervical / upper / mid / lower thoracic)
- Span of tumour — longitudinal extent
- % involvement of luminal circumference — circumferential vs partial
- Whether the scope can pass through — complete obstruction implies advanced disease and affects further investigations (e.g., EUS probe may not pass)
The biopsy provides:
- Histological type — SCC vs ADC (critical because management pathways differ)
- Degree of differentiation — well / moderately / poorly differentiated
- Molecular markers — HER2 status (for ADC, determines eligibility for trastuzumab), PD-L1 (immunotherapy eligibility), MSI status
Biopsy is Non-Negotiable
Biopsy should be taken for all lesions in the esophagus irrespective of how trivial they appear and the indication for the examination [1]. A senior will never forgive you for scoping a patient, seeing a lesion, and not biopsying it. Even if it looks like benign esophagitis, take tissue — early malignancy can be subtle.
The algorithm follows the three goals above in a stepwise fashion. You don't jump to PET-CT before confirming malignancy on biopsy.
Staging Is Only for Patients Fit for Curative Treatment
Staging investigations are only indicated for patients suitable for potentially curative therapies [1]. If a patient is clearly unfit for any treatment (e.g., severe comorbidities, widely disseminated disease obvious on clinical examination), extensive staging adds cost, delay, and discomfort without changing management.
3. Investigation Modalities — Detailed Breakdown
Before any investigation, a thorough clinical assessment guides the workup:
| Domain | What to Look For | Why |
|---|---|---|
| General examination | Pallor (chronic blood loss or malnutrition); Jaundice (liver metastasis); Dehydration and cachexia (hydration and nutritional status) [1] | Determines fitness for surgery and identifies metastatic disease |
| Lymphadenopathy | Left supraclavicular lymph node (Virchow's node) — since the lymphatic drainage is through the thoracic duct [1] | Enlarged supraclavicular LN indicates disseminated disease — finding this on examination may preclude curative surgery |
| Abdominal examination | Abdominal scars (previous surgery affects choice of surgical approach); Hepatomegaly (liver metastasis); Ascites (liver metastasis / peritoneal seeding); PR examination (look for rectal deposits) [1] | Identifies metastatic disease and surgical planning |
| Neurological examination | Evaluation of neuromuscular causes of dysphagia [1] | Rules out oropharyngeal/functional causes |
| Voice assessment | Hoarseness | Suggests RLN invasion → locally advanced disease |
| Test | Purpose | Interpretation |
|---|---|---|
| CBC with differentials [1] | Detect anemia (iron deficiency from chronic bleeding); assess WBC for infection (aspiration pneumonia); platelet count for pre-op | Microcytic hypochromic anemia → chronic blood loss |
| Clotting profile [1] | Pre-operative assessment before OGD and surgery | Coagulopathy → bleeding risk; may indicate liver dysfunction |
| Electrolyte profile [1] | Assess for electrolyte abnormalities due to vomiting | Hypokalemia, hypochloremic metabolic alkalosis from persistent vomiting |
| LFT [1] | Albumin and pre-albumin to evaluate nutritional status; evaluate for possible liver metastasis [1] | Low albumin → malnutrition (surgical risk factor); raised ALP/GGT/bilirubin → liver mets |
| RFT [1] | Assess pre-renal causes of dehydration | Raised urea:creatinine ratio → pre-renal AKI from dehydration |
| Lung function test [1] | Assess pulmonary function before surgery | FEV1 < 1.25 L is a poor candidate for thoracotomy — 40% risk of death from respiratory failure within 4 years [1]; transhiatal approach should be considered instead |
| Tumour markers (CEA, CA19-9) [9] | Not diagnostic; used for follow-up and monitoring recurrence | Elevated pre-op level → useful as a baseline for post-treatment surveillance |
| Laryngoscopy [2] | Baseline vocal cord status before any treatment | Documents pre-existing RLN dysfunction; critical before surgery or radiotherapy that may affect the RLN |
FEV1 Cut-off — A High-Yield Surgical Pearl
Patients with FEV1 < 1.25 L are poor candidates for thoracotomy because there is a 40% risk of death from respiratory failure within 4 years. In such patients, transhiatal (THE) esophagectomy should be considered since the pulmonary morbidity is less than thoracotomy [1]. This is because THE avoids opening the chest (thoracotomy), so there is less post-operative pulmonary compromise. The patient factor counterpart from Maxim's notes: FEV1 > 1.5 L is the typical threshold considered safe for thoracotomy [2].
This is the cornerstone investigation — it simultaneously diagnoses and provides tissue.
| Aspect | Detail |
|---|---|
| Principle | Direct visualization of the esophageal mucosa + tissue acquisition |
| Indication | Any patient with progressive dysphagia — OGD is the first-line investigation [1] |
| What to document | Distance from incisors; tumour length; circumferential extent; whether scope passes through; relationship to the Z-line (for EGJ tumours) [2] |
| Biopsy protocol | Multiple biopsies from the mass (at least 6–8 from different areas of the lesion, including the margin); biopsy should be taken for all lesions irrespective of how trivial they appear [1] |
Advanced Endoscopic Techniques
| Technique | How It Works | When to Use |
|---|---|---|
| Chromoendoscopy with Lugol's iodine [1] | Lugol's iodine has an affinity for glycogen in squamous epithelium. Normal squamous epithelium with glycogen stains dark-brown/green-brown. Absence of dye uptake occurs when glycogen is depleted — as in inflammatory change, dysplasia, or early malignancy [1] | Commonly used in esophagus for detection of squamous dysplasia and early SCC [1]; guides EMR of early SCC by revealing extent and delineation of a lesion [1] |
| Narrow-band imaging (NBI) [1] | High-resolution endoscopic technique that enhances fine structures of the mucosal surface without the use of dyes [1] — uses optical filters to select specific wavelengths of light (blue 415 nm and green 540 nm) that are preferentially absorbed by hemoglobin, highlighting superficial capillary patterns and mucosal architecture | Enhances detection of subtle mucosal irregularities, dysplasia, and early cancers; useful adjunct to white-light endoscopy |
Why Lugol's staining works — from first principles: Normal squamous epithelial cells are packed with intracellular glycogen. Lugol's iodine (I₂ + KI) reacts with glycogen to produce a brown-black colour. Dysplastic or malignant squamous cells have depleted glycogen (because rapidly dividing cells consume their glycogen stores). Therefore, malignant areas appear as unstained (pale/yellow) patches against a dark-stained background — making them easy to spot and biopsy.
Advantages [1]: Direct visualization; combination of histology and cytology from biopsy provides high diagnostic accuracy.
Disadvantages [1]: Only the mucosal surface can be studied and biopsied — cannot assess depth of invasion or extramural spread (that's what EUS and CT are for).
| Aspect | Detail |
|---|---|
| Principle | Patient swallows radio-opaque contrast; fluoroscopic imaging shows mucosal outline and motility in real-time |
| Indication | Assess for tumour complications such as tracheoesophageal fistula [1]; suspected proximal esophageal lesion; known complex tortuous stricture; negative OGD but mechanical obstruction still suspected [1] |
| Typical findings in CA esophagus | Proximal dilatation, mucosal irregularity, and annular constriction [1] — "apple-core" or "rat-tail" appearance with irregular shouldering (sharp cut-off with irregular margins) |
| When to use which contrast | Barium: better mucosal coating, higher resolution; avoid if risk of perforation — barium peritonitis [6]. Gastrografin: safe for suspected perforation, but may cause chemical pneumonitis if aspirated [6]. Omnipaque (low-osmolarity water-soluble): use if high risk of aspiration — lower risk of pulmonary oedema compared to gastrografin [6] |
Barium vs Gastrografin vs Omnipaque — Know When to Use What
Think of it as a hierarchy of safety:
- No risk of perforation or aspiration → Barium (best image quality)
- Risk of perforation → Gastrografin (water-soluble, won't cause peritonitis)
- Risk of aspiration → Omnipaque (water-soluble AND low osmolarity, safest for the lungs)
Never use barium if you suspect a TE fistula — barium in the mediastinum or peritoneum is catastrophic.
EUS is the best investigation for locoregional staging (T and N) — it combines the endoscopic view with high-frequency ultrasound to image the esophageal wall layers and surrounding structures.
| Aspect | Detail |
|---|---|
| Principle | High-frequency ultrasound probe at the tip of an endoscope; images the 5 sonographic layers of the esophageal wall (mucosa, submucosa, muscularis propria, adventitia) and surrounding tissues |
| T staging | Assess depth of tumour penetration through the esophageal wall [1]: T1–T3 (spread through wall layers) and T4 (invasion of adjacent organs) [1] |
| T1a vs T1b distinction | T1a MUST be distinguished from T1b cancer since the chance of lymph node metastasis in T1b cancer is so high that open surgery is required [1] — T1a (confined to mucosa) can be treated with EMR/ESD; T1b (submucosa) needs esophagectomy |
| N staging | Metastasis to lymph node (N0 or N1) [1]; EUS-guided FNAC of suspicious LN — features suggesting malignancy: hypoechoic, > 1 cm, spherical, homogeneous [2] |
| Other uses | Can implant metallic markers for delineation of RT fields [2]; superior to CT in locoregional staging [1] |
| Limitation | Cannot pass through tight stenosis (if scope doesn't pass, cannot stage distally); operator-dependent; does not assess distant metastasis |
Why EUS is superior to CT for T/N staging: CT relies on size criteria for lymph nodes ( > 1 cm = suspicious), which misses micrometastases in normal-sized nodes. EUS can assess the internal echo pattern of nodes (hypoechoic, homogeneous nodes are more likely malignant regardless of size) and enables tissue confirmation via FNAC. For T staging, CT cannot reliably distinguish the individual wall layers, whereas EUS shows them clearly.
| Aspect | Detail |
|---|---|
| Principle | Cross-sectional imaging with IV contrast to assess tumour extent, regional invasion, and distant metastasis |
| T staging | Assess locoregional staging especially to distinguish T4 lesion [1] — CT excels at showing whether the tumour invades resectable structures (pleura/pericardium/diaphragm = T4a) vs unresectable structures (aorta/trachea/bronchus/spine = T4b) [1] |
| M staging | Modality of choice to assess M stage [1] — identifies liver metastases, lung metastases, adrenal metastases, distant lymphadenopathy |
| N staging | Modality used to identify regional or distant metastasis [1] — but limited by size criteria (misses small positive nodes) |
| Role | CT whole body with contrast: for locoregional involvement (T3/4) and distant metastasis (M) [2] |
CT vs EUS: CT is better for M staging and assessing T4 invasion into surrounding structures (fat plane obliteration, aortic contact angle). EUS is better for T1–T3 depth assessment and N staging. They are complementary, not competing.
| Aspect | Detail |
|---|---|
| Principle | Relies on high metabolic activity of tumours compared with normal tissues [1] — radiopharmaceutical agents (¹⁸F-FDG) enter highly metabolically active cells and are phosphorylated. The phosphorylated product is a highly polar molecule and cannot easily diffuse out of cells [1] → accumulates in tumour cells → appears as "hot spots" |
| M staging | Assess distant metastasis staging (M) [1]; similar sensitivity as CT for distant metastasis [2] |
| Treatment response | Can assess metabolic activity after neoadjuvant chemoRT / detect recurrence [2] |
| Caveats | May pick up additional signals (e.g., reactive hilar LN due to smoking) [2] → false positives; limited in detecting brain metastases (high baseline glucose uptake); mucinous tumours may be FDG-negative |
Why PET-CT adds value over CT alone: CT detects metastases based on size and morphology (you need a visible mass). PET-CT detects metastases based on metabolic activity — a normal-sized lymph node that is metabolically active will light up on PET, potentially upstaging the disease and preventing futile surgery.
| Aspect | Detail |
|---|---|
| Indication | Indicated in patients with suspected tracheoesophageal fistula who present with choking [1]; indicated in patients with tumour located in the upper and middle 1/3 of esophagus since it is in close proximity to trachea and its bifurcation [1] |
| Not routinely done | NOT routinely performed because CXR is more sensitive to detect synchronous or metastatic tumour in the lung [1] |
| Tumour in distal 1/3 | Tumour located in the distal 1/3 esophagus is unlikely to invade into bronchus [1] — therefore bronchoscopy is not indicated |
| Key finding | Tracheal invasion [2] — may require stenting before RT to prevent iatrogenic tracheoesophageal fistula [2]. This is because radiotherapy can cause tumour necrosis, and if the tumour is invading the airway, necrosis creates a fistula between the esophagus and trachea. Placing a stent first provides structural support. |
| Aspect | Detail |
|---|---|
| Indication | Recommended for OGJ tumours (adenocarcinoma) for hepatic/peritoneal seeding [2]; useful for diagnosis of occult hepatic and peritoneal metastasis [1] |
| Key advantage | Only modality reliably able to detect peritoneal tumour seedlings [1] — CT and PET-CT frequently miss small peritoneal deposits |
| Technique | Direct visualization of the peritoneal cavity + biopsy of suspicious lesions; peritoneal washing for cytology (positive cytology = M1 disease) |
| Aspect | Detail |
|---|---|
| Purpose | Evaluate for possible lung metastasis and presence of pleural effusions; look for soft-tissue mass causing extramural dysphagia (e.g., bronchogenic carcinoma); aspiration pneumonia [1] |
| Limitation | Low sensitivity for small metastases — CT is far superior; but CXR is cheap, quick, and available, making it a good baseline screening tool |
| Aspect | Detail |
|---|---|
| Role | Limited in esophageal cancer staging |
| Reason | MRI has intrinsic motion artifact when imaging the thorax/upper abdomen (cardiac motion, respiratory motion) [1] → image quality is degraded; CT is preferred |
| Possible use | Selected cases for liver lesion characterisation (if CT is equivocal); pelvic staging if needed |
Staging work-up: EUS + PET-CT (neck + thorax + abdomen) [2]
| Investigation | Primary Role | Best For |
|---|---|---|
| EUS | T and N staging | Best for T and N staging → determines need for neoadjuvant chemoRT [2] |
| CT thorax + abdomen with contrast | T4 assessment, M staging | Mandatory for M staging but not accurate for T1–T3 [2] |
| PET-CT | M staging, treatment response | Distant metastasis detection; post-treatment assessment [2] |
| Bronchoscopy | Airway invasion | Upper/mid tumours — detect tracheal invasion [2] |
| Diagnostic laparoscopy | Peritoneal/hepatic staging | OGJ adenocarcinomas — detect peritoneal seeding [2] |
| USG neck | Cervical LN | Cervical lymphadenopathy assessment [2] |
| Laryngoscopy | Vocal cord function | Baseline vocal cord status before treatment [2] |
This is the "can the patient survive the operation?" assessment:
| Assessment | What It Tells You | Key Thresholds |
|---|---|---|
| ECG / Echocardiography [1] | Cardiopulmonary reserve | Assess for ischaemic heart disease, valvular disease, LV function |
| Lung function test (FEV1) [1] | Pulmonary reserve | FEV1 < 1.25 L → poor candidate for thoracotomy (40% risk of respiratory death within 4 years) → consider transhiatal approach [1]; FEV1 > 1.5 L is generally considered safe [2] |
| CXR, ABG [2] | Baseline respiratory function | Identify COPD, effusion, consolidation |
| Nutritional assessment | Surgical risk stratification | Albumin < 30 g/L → high surgical risk; BMI; weight loss > 10% in 6 months; consider pre-operative nutritional supplementation (enteral/parenteral) |
| Exercise tolerance [2] | Functional capacity | > 2 flights of stairs is a rough guide to adequate cardiorespiratory fitness [2] |
| Performance status | Overall fitness | ECOG/WHO performance status; Karnofsky performance score |
| Modality | Classic/Key Finding in CA Esophagus |
|---|---|
| OGD | Irregular, friable, ulcerated or fungating mucosal mass; may have shouldered margins; scope may not pass (complete obstruction); document distance from incisors, length, circumference |
| Chromoendoscopy (Lugol's) | Unstained (pale/yellow) patches amid dark-stained normal mucosa — indicates glycogen depletion in SCC/dysplasia |
| NBI | Irregular intrapapillary capillary loop (IPCL) pattern — brownish dots/lines on enhanced mucosal surface |
| Barium swallow | "Apple-core" lesion (annular constriction with irregular shouldering + proximal dilatation); TE fistula (contrast leaking into bronchial tree) |
| EUS | Hypoechoic mass disrupting normal wall layer architecture; depth of invasion through 5 layers; hypoechoic, > 1 cm, spherical, homogeneous LNs |
| CT | Wall thickening, luminal narrowing; fat plane obliteration with adjacent structures (T4); liver/lung/adrenal metastases |
| PET-CT | FDG-avid mass in the esophagus; distant FDG-avid foci (metastases); useful for response assessment post-neoadjuvant |
| Bronchoscopy | Extrinsic compression, mucosal invasion, or visible fistula in the trachea/bronchus |
| Laparoscopy | Peritoneal nodules, liver surface deposits; positive peritoneal cytology |
High Yield Summary — Diagnostics
- Diagnosis = OGD + biopsy — always first-line; document distance from incisors, tumour span, circumferential involvement, whether scope passes through. Biopsy ALL lesions.
- Chromoendoscopy (Lugol's iodine) — highlights SCC/dysplasia as unstained areas (glycogen depletion). NBI enhances mucosal capillary patterns without dye.
- Staging = EUS + CT + PET-CT — EUS for T and N (best); CT for T4 and M (mandatory); PET-CT for M and treatment response.
- EUS: T1a vs T1b is the critical distinction — T1a → endoscopic therapy; T1b → esophagectomy (20–25% chance of LN metastasis).
- T4a (resectable: pleura, pericardium, diaphragm) vs T4b (unresectable: aorta, trachea, spine) — CT is best for this distinction.
- Bronchoscopy — for upper/mid tumours to detect tracheal invasion; may need stenting before RT to prevent iatrogenic TE fistula.
- Diagnostic laparoscopy — for OGJ/adenocarcinoma; only reliable way to detect peritoneal seeding.
- FEV1 < 1.25 L → avoid thoracotomy → consider transhiatal esophagectomy.
- Contrast choice: Barium (best image) → Gastrografin (if perforation risk) → Omnipaque (if aspiration risk).
Active Recall - Diagnostics and Staging of CA Esophagus
References
[1] Senior notes: felixlai.md (Esophageal cancer sections — Diagnosis, Radiological tests, OGD overview, Barrett's diagnostic criteria, Dysphagia history taking) [2] Senior notes: maxim.md (CA esophagus — Investigations and Staging, Dysphagia investigations, OGD section, Barrett's oesophagus, Contrast agents) [6] Senior notes: maxim.md (Dysphagia investigations — Barium vs Gastrografin vs Omnipaque) [9] Lecture slides: GC 212. Weight loss and vomiting gastric cancer; abdominal imaging.pdf (Investigations and Clinical staging slides)
Management of CA Esophagus
Before diving into modalities, internalise the framework that drives every management decision. There are three factors that determine treatment [1]:
- Tumour factor — size, location (upper/mid/lower 1/3, cardia), presence of lymph node metastasis, invasion into adjacent major organs (resectable vs unresectable) [1][2]
- Patient factor — age, comorbidities, lung function (FEV1 > 1.5 L), exercise tolerance ( > 2 flights of stairs), smoking status, nutritional status [2]
- Surgeon/organ factor — experience of surgeon, hospital equipment, method of reconstructing esophagus [2]
And there are three treatment objectives [1]:
- Local control = resection of tumour with negative (clear) resection margin
- Regional control = lymph node dissection
- Systemic control = NOT indicated for CA esophagus (i.e., there is no role for routine adjuvant systemic chemotherapy in isolation unlike, say, colon cancer — but neoadjuvant and definitive chemoradiation play major roles)
The fundamental decision is curative vs palliative:
- Early stage cancer should be offered curative treatment (surgery ± neoadjuvant, or radical chemoRT)
- Advanced stage cancer should be offered palliative care [1]
Key Principle
Surgery alone produces few cures in either squamous cell or adenocarcinoma except in the earliest stages of disease [1]. This is why multimodality treatment (neoadjuvant chemoRT + surgery) is the standard of care for locally advanced but resectable disease.
| Stage | TNM | Treatment |
|---|---|---|
| 0 | Tis, N0, M0 | Tis/T1a (confined to mucosa): EMR / ESD [2] |
| I | T1, N0, M0 | T1b (invades submucosa): esophagectomy [2]; low-risk cT1b–T2 N0 may proceed directly to surgery [3] |
| II | T2–3, N0, M0 or T1–2, N1, M0 | Operable SCC: neoadjuvant chemoRT (CROSS) + esophagectomy [2][3] |
| Operable ADC: perioperative FLOT (preferred) or neoadjuvant chemoRT (CROSS) + esophagectomy [3] | ||
| Inoperable SCC: upfront chemoRT ± esophagectomy (if downstaged) [2] | ||
| III | T3–T4a, any N, M0 | Operable ADC: perioperative FLOT ± durvalumab (if PD-L1+) → esophagectomy [3] |
| Operable SCC: neoadjuvant chemoRT (CROSS) → esophagectomy [3] | ||
| Inoperable: definitive chemoRT [2] | ||
| Adjuvant nivolumab if residual pathologic disease after neoadjuvant chemoRT + R0 resection [3] | ||
| IV | any T, any N, M1 | Esophageal balloon dilation ± stenting; Palliative chemoRT [2] |
Detailed Treatment Modalities
"Endoscopic" → from Greek endo- (within) + skopein (to look) — you're treating from inside the lumen.
| Feature | Detail |
|---|---|
| Principle | Remove the superficial tumour through the endoscope, preserving the native esophagus |
| Indications | Superficial cancer limited to mucosa (T1a) but NOT for more advanced cancer since the chance of lymph node metastasis is too high [1]; patients who prefer esophageal preservation [1] |
| Critical cut-off | Tumour invasion into submucosa (T1b), even without visible LN involvement, should receive esophagectomy with LN dissection due to high frequency (20–25%) of concurrent findings of positive LNs [1] |
| Advantages | Esophageal preservation and reduced post-treatment mortality [1]; less invasive, safe, and highly effective (90% survival) [2] |
| Disadvantages | Technically demanding and lack of long-term outcomes and recurrence data [1] |
EMR vs ESD:
| EMR | ESD | |
|---|---|---|
| Technique | Snare resection after submucosal injection (hyaluronic acid + saline) to elevate the lesion [2] | Dissect lesions from the submucosa using an insulated-tip knife [1] |
| Size limit | Not effective for lesions > 2 cm — piecemeal resection is necessary → increased complications, impossible to conclusively assess completeness of lateral resection margin [1] | Can remove larger lesions intact (en-bloc) [1] |
| En-bloc rate | Lower | Higher en-bloc resection rate [2] |
| Complications | Lower | Higher (bleeding, perforation, stricture) |
T1a vs T1b — The Most Important Staging Decision
This single distinction changes everything: T1a → endoscopic therapy (organ-sparing); T1b → major surgery (esophagectomy). Why? Because the submucosa contains the dense lymphatic plexus. Once tumour reaches the submucosa, the probability of lymph node metastasis jumps to 20–25%, making endoscopic therapy inadequate (it doesn't remove lymph nodes). This is why EUS is performed before deciding on endoscopic vs surgical treatment.
B. Esophagectomy with Reconstruction and LN Dissection [1][2]
This is the definitive curative surgery. It is a major operation with significant morbidity (30–50%) and mortality (2–5% in high-volume centres).
| Approach | Technique | Key Features |
|---|---|---|
| Ivor-Lewis (2-stage, transthoracic) [1] | Step 1: Upper midline abdominal incision — mobilise stomach, divide left gastric artery and LNs, create gastric conduit. Step 2: Right thoracotomy (entry above 5th rib) — gives excellent access to mediastinum and thoracic inlet [1]; esophagectomy + intrathoracic esophagogastric anastomosis | Best for mid/lower thoracic tumours; allows direct vision thoracic lymphadenectomy; anastomosis is intrathoracic (risk: if it leaks → mediastinitis) |
| McKeown (3-stage, transthoracic) [1] | Step 1: Abdominal — same as Ivor-Lewis. Step 2: Right thoracotomy — esophagectomy. Step 3: Neck incision — cervical esophagogastric anastomosis | Best for upper thoracic tumours where you need a proximal resection margin in the neck; cervical anastomosis is safer if it leaks (drains externally rather than into mediastinum); but higher risk of anastomotic leak (10%) because gastric conduit has more tension and poorer blood supply [2] |
| Transhiatal (THE) [1][2] | Esophagectomy without a thoracotomy [1]; stomach mobilised via midline abdominal incision; diaphragm opened from abdomen; lower esophagus mobilised under direct vision; upper esophagus mobilised by blunt dissection; cervical anastomosis via neck incision | Provides removal of tumour and LN in the lower mediastinum ONLY but not in upper or middle mediastinum [1]; unsuitable for SCC (usually needs full mediastinal lymphadenectomy); advantages: reduced risk of pneumonia, suitable for poor lung function [2]; rarely done now [2] |
Why can the esophagus be mobilised by blunt dissection? Because the esophagus has segmental blood supply by small vessels only [1] — these can be divided sequentially without catastrophic bleeding, unlike the aorta or major visceral arteries.
- Lymph node dissection is mandatory in all approaches [1]
- Resection margin should be generous since CA esophagus is NOTORIOUS for submucosal spread [1] — aim for ≥ 5 cm proximal and distal margins; intraoperative frozen section of margins is standard
- Extent of lymphadenectomy [2]:
- 10 cm proximal and 5 cm distal to macroscopic tumour
- 2-field dissection: Field 1 (cervical) and Field 2 (mediastinal) for upper 1/3 tumours; Field 2 (mediastinal) and Field 3 (abdominal/celiac) for lower 1/3 tumours [2]
Fields of LN dissection [2]:
- Field 1: Cervical LN
- Field 2: Mediastinal LN
- Field 3: Intra-abdominal (celiac) LN
After removing the esophagus, you need to reconstruct the alimentary tract. The stomach is the preferred conduit:
- Gastric mobilisation [2]: ligate left-sided blood supply (short gastric artery, left gastric artery, left gastroepiploic artery) — the conduit survives on the right gastroepiploic artery and right gastric artery
- Route: bring gastric conduit up via native tract of esophagus (lowest tension, best blood supply) or retrosternal / subcutaneous routes if re-operating [2]
- Pyloroplasty: improve gastric emptying post-op [2] — the vagus nerves are inevitably transected during esophagectomy → vagal denervation → gastric stasis; pyloroplasty bypasses this
- Insert feeding jejunostomy tube [2] — post-operative nutrition while the anastomosis heals
- Alternative conduit: colonic interposition (e.g., previous gastrectomy, post-leakage) — needs bowel prep and antibiotics [2]
- Thoraco-abdominal approach: for very distal tumours; limited by arch of aorta
- Pharyngo-laryngo-oesophagectomy (PLO): for very proximal tumours; requires permanent tracheostomy and voice rehabilitation → primary chemoRT is preferred now [2]
| Tumour Location | Preferred Approach | Rationale |
|---|---|---|
| Upper 1/3 | McKeown (3-stage) or primary chemoRT | Need proximal margin in the neck; PLO reserved for selected cases |
| Middle 1/3 | McKeown or Ivor-Lewis | Both allow adequate mediastinal access |
| Lower 1/3 / Siewert Type I | Transthoracic en bloc esophagectomy + partial gastrectomy + 2-field lymphadenectomy [1] | Distal ADC arising from Barrett's |
| Siewert Type II | Transabdominal/transhiatal resection of distal esophagus + total gastrectomy + lymphadenectomy of lower mediastinum and abdominal D2 nodal compartment [1] | True cardia cancer |
| Siewert Type III | Same as Type II [1] | Subcardial gastric cancer infiltrating upward |
| Phase | Measures |
|---|---|
| Pre-operative | Encourage respiratory muscle exercise; smoking cessation [1] |
| Intraoperative | Prevent prolonged operation (→ atelectasis from mucus accumulation); prevent infusion of large amount of fluid (→ pulmonary oedema) [1] |
| Post-operative | Encourage respiratory muscle exercise (deep breathing exercise); encourage coughing (→ prevent sputum retention); chest physiotherapy; pain control (PCA, thoracic epidural analgesia); early mobilisation [1] |
C. Chemotherapy and Radiotherapy [1][2][3]
Neoadjuvant / Perioperative Therapy — NCCN v2.2026 Update
Neoadjuvant therapy is indicated for locally advanced, resectable esophageal cancer. The approach differs by histologic subtype (adenocarcinoma vs SCC) and clinical stage [3]:
Indications for neoadjuvant therapy [3][4]:
- Adenocarcinoma: cT2 N0 with high-risk features (LVI, ≥ 3 cm, poorly differentiated), cT1b–T2 N+, or cT3–T4a any N
- SCC: cT2 N0 with high-risk features, cT1b–T2 N+, or cT3–T4a any N
- Low-risk cT1b–T2 N0 lesions may proceed directly to surgery [4]
Why "neoadjuvant" (before surgery) rather than "adjuvant" (after surgery)?
- Post-operatively, the patient is recovering from a massive operation → may not tolerate chemotherapy
- The tumour has its own blood supply intact pre-operatively → chemotherapy drugs reach the tumour more effectively
- Neoadjuvant treatment can shrink the tumour → making surgery technically easier with better resection margins
- The pathological response to neoadjuvant therapy provides prognostic information (complete pathological response = excellent prognosis)
| Regimen | Detail |
|---|---|
| FLOT (preferred) | Fluorouracil + leucovorin + oxaliplatin + docetaxel — category 1 [3]. Pre-op FLOT × 4 cycles → surgery → post-op FLOT × 4 cycles. The FLOT4 trial demonstrated a 9% improvement in 3- and 5-year overall survival over ECF/ECX [3][4]. Now the standard perioperative regimen for esophageal and EGJ ADC |
| FLOT + durvalumab | For PD-L1 CPS ≥ 1 or TAP ≥ 1% — category 1 for EGJ ADC; category 2A for esophageal ADC [3] |
| Other recommended | Fluorouracil/cisplatin (category 1); fluoropyrimidine/oxaliplatin [3] |
FLOT — The New Standard for Adenocarcinoma
FLOT is the preferred perioperative chemotherapy regimen for esophageal and EGJ adenocarcinoma [3]. It is a triplet cytotoxic regimen that should be reserved for medically fit patients with excellent performance status and access to frequent toxicity evaluations, as grade 3–4 neutropenia occurs in up to 85% of patients [5]. For less fit patients, doublet regimens (fluoropyrimidine/oxaliplatin or fluoropyrimidine/cisplatin) are recommended alternatives.
| Regimen | Detail |
|---|---|
| Paclitaxel + carboplatin + RT (preferred) | 41.4–50.4 Gy concurrent radiation — category 1 [3]. This is the CROSS regimen, which showed significant OS benefit (HR 0.73 for adenocarcinoma; HR 0.48 for SCC) [4] |
| Fluorouracil + oxaliplatin + RT | Category 1 [3] |
| Other recommended | Fluorouracil/cisplatin + RT (category 1); irinotecan/cisplatin + RT (category 2B) [3] |
CROSS Protocol — Key Details
The CROSS trial (van Hagen et al.) established neoadjuvant chemoradiation as standard of care for locally advanced esophageal cancer. Regimen: paclitaxel + carboplatin weekly × 5 weeks with concurrent 41.4 Gy radiation → surgery. Median OS was 49.4 months (chemoRT + surgery) vs 24.0 months (surgery alone). The benefit was especially pronounced for SCC (HR 0.48), but also significant for ADC (HR 0.73) [4].
- Preoperative chemoradiation is preferred over perioperative chemotherapy alone for SCC [3]
- The JCOG1109 (NExT) trial compared neoadjuvant cisplatin/5-FU (CF) vs CF + docetaxel (DCF) vs CF + radiation (CF-RT) for esophageal SCC. DCF showed the most favourable outcomes [5]
- SCC is more radiosensitive than ADC → chemoRT achieves higher pathological complete response rates in SCC
SCC vs ADC — Treatment Strategy Difference
SCC is more sensitive to chemoRT; ADC is less sensitive to chemoRT → surgery is the backbone for ADC [2]. For SCC, neoadjuvant chemoradiation (CROSS) is preferred. For ADC, perioperative chemotherapy (FLOT) is the preferred approach, though neoadjuvant chemoRT (CROSS) is an acceptable alternative [3]. Recent data from the ESOPEC trial suggests FLOT may be superior to CROSS for ADC, and the Neo-AEGIS trial adds further evidence to this comparison.
For tumours with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR), neoadjuvant immunotherapy options include:
- Dostarlimab
- Nivolumab + ipilimumab
- Pembrolizumab
- Tremelimumab + durvalumab
| Feature | Detail |
|---|---|
| Regimen | Nivolumab — category 1 [3] |
| Indication | After preoperative chemoradiation → R0 resection with residual pathologic disease (i.e., did NOT achieve complete pathological response) |
| Trial | CheckMate 577 — significantly improved disease-free survival with adjuvant nivolumab for 1 year post-esophagectomy [3] |
| Regimen | Key Toxicities | Grade ≥ 3 Rate | Notes |
|---|---|---|---|
| FLOT | Neutropenia, febrile neutropenia (~16%), nausea/vomiting, diarrhoea, peripheral neuropathy (oxaliplatin), mucositis | ~85% grade 3–4 neutropenia with triplet docetaxel [5] | Treatment discontinuation in ~9%; reserve for fit patients [3][5] |
| CROSS (paclitaxel/carboplatin + RT) | Radiation esophagitis (up to 84%, mostly grade 1–2), leukopenia (~57%), anaemia (~68%), nausea/vomiting (~64%), anorexia (~57%) | ~45% neutropenia; ~61% esophagitis [6] | Post-op pulmonary complications ~21%, anastomotic leakage ~12% [6]; increased chylothorax risk vs chemo alone [7] |
| CRT + immunotherapy | All CRT toxicities + rash (~25%), fatigue (~16%), thyroid dysfunction, immune-mediated pneumonitis/hepatitis/colitis | ~20% grade 3–4 [6] | Potentially serious immune-mediated AEs require monitoring |
Long-term sequelae include chemotherapy-induced neuropathy, radiation-induced cardiotoxicity, and fatigue [3].
| Feature | Detail |
|---|---|
| Rationale | Eradicate residual tumour at resection margin; decreases risk of local recurrence [1] |
| When | Considered if positive margins (R1 resection), node-positive disease, or poor prognostic features on final pathology |
| Feature | Detail |
|---|---|
| Indication | Inoperable SCC; patients not fit for surgery (e.g., poor lung function) [2] |
| Key point | Radical radiotherapy is ALSO curative [1] — this is important to remember. For SCC especially, definitive chemoRT can achieve cure rates approaching surgery in selected patients |
| Regimen | Cisplatin + 5-fluorouracil + > 50 Gy RT [2] |
| SCC vs ADC | SCC is more sensitive to chemoRT [2]; ADC is less sensitive to chemoRT → surgery is preferred [2] |
These are increasingly important, especially for advanced/metastatic disease:
| Agent | Target | Indication |
|---|---|---|
| Trastuzumab (Herceptin) | HER2 receptor | HER2-positive ADC (overexpressed in ~20% of esophageal/EGJ ADC); added to first-line chemotherapy |
| Ramucirumab | VEGFR-2 | Second-line for advanced ADC; anti-angiogenic |
| Nivolumab / Pembrolizumab | PD-1 | PD-L1-positive or MSI-high tumours; first-line treatment (CheckMate 649, KEYNOTE-590); adjuvant nivolumab post-neoadjuvant chemoRT + surgery (CheckMate 577) [3] |
| Durvalumab | PD-L1 | Added to perioperative FLOT for PD-L1 CPS ≥ 1 or TAP ≥ 1% in EGJ/esophageal ADC [3] |
| Dostarlimab / Tremelimumab | PD-1 / CTLA-4 | Neoadjuvant options for MSI-H/dMMR tumours [3] |
Indications [1]:
- Patients with metastatic cancer (M1)
- Cancers invading adjacent organs that are unresectable (T4b)
The goals are to relieve dysphagia, maintain nutrition, control symptoms, and improve quality of life.
| Modality | Detail | Key Points |
|---|---|---|
| Esophageal dilation + stenting [1][2] | Self-expanding metallic stents (SEMS) with silicone coating placed endoscopically to palliate significant dysphagia [2] | NOT suitable for tumours long in size (poor functional peristalsis) or located in the cervical esophagus (discomfort) [1]; complications: perforation, erosion, obstruction of tube, or migration of stent [1]; unable to give RT after stenting [2] |
| Endoluminal ablation [1][2] | Laser ablation, argon plasma coagulation (APC) — restore esophageal lumen successfully 90% of the time with only a 4–5% perforation rate [1]; also used to open lumen / unblock stent [2] | |
| Radiotherapy [1][2] | External beam RT or brachytherapy (intraluminal RT) [2]; SCC is usually radiosensitive whereas ADC is less responsive [1] | First choice for palliation of EGJ cancers since stents placed across the EGJ are associated with higher chance of gastroesophageal reflux [1] |
| Chemotherapy [1] | Current regimens include cisplatin + 5-fluorouracil (5-FU) [1]; palliative chemoRT for symptom control | |
| Nutritional support [1][2] | PEG (percutaneous endoscopic gastrostomy), jejunostomy tube (PEJ), NG tube, open gastrostomy [1][2] | Essential for maintaining caloric intake when the esophagus is completely obstructed |
| Best supportive care | Pain management, anti-emetics, psychosocial support | For patients with very advanced disease or poor performance status |
Why NOT Stent Across the EGJ?
Stents placed across the EGJ are associated with higher chance of gastroesophageal reflux [1]. This makes sense: the stent holds the EGJ permanently open, abolishing the physiological sphincter mechanism. The patient then suffers intractable reflux on top of their cancer. For EGJ tumours, palliative RT (especially brachytherapy) is preferred because it shrinks the tumour without permanently propping the sphincter open.
Since Barrett's is the precursor lesion for ADC, its management is essentially cancer prevention:
- ALL patients with Barrett's esophagus should receive PPI whether they are symptomatic or not [1]
- Non-dysplasia: endoscopic surveillance every 3–5 years [1][2]
- Low-grade dysplasia: endoscopic surveillance every 6 months for one year then annually if negative [1]; OR EMR + endoscopic radiofrequency ablation (RFA) to ablate remaining metaplastic epithelium [1]
- High-grade dysplasia: EMR + RFA [1]; or esophagectomy — only therapy that removes all neoplastic epithelium along with any occult malignancy and regional LNs but associated with high procedure-related morbidity and mortality [1]
Complications of Esophagectomy [2]
Understanding complications is essential because they are commonly tested and because anticipating them guides peri-operative management.
| Complication | Incidence | Mechanism / Detail | Management |
|---|---|---|---|
| Post-op pneumonia | 20% | Due to smoker status, thoracotomy, one-lung ventilation, vocal cord palsy [2] | Antibiotics, chest physiotherapy, incentive spirometry |
| Reactionary bleeding | Uncommon | Transection of azygos vein / aortic branches to esophagus [2] | Surgical re-exploration |
| Anastomotic leak | 10% | Risk factors: poor blood supply of esophagus, tension of conduit, absence of serosa, use of neoadjuvant RT, surgeon technique [2] | NPO, IV fluids, TPN, antibiotics, monitor drain output; conservative: lay open for drainage (three-stage only); endoscopic: stenting, EndoSponge [2] |
| Conduit ischaemia | Suspect if sepsis or metabolic acidosis within first 24 hours [2]; prevention: intraoperative ICG (indocyanine green fluorescence to assess conduit perfusion) [2] | Conservative if mild (Types 1/2); take down anastomosis if severe (Type 3): cervical esophagostomy + resection of ischaemic conduit [2] | |
| RLN injury | 20% | During LN dissection [2] — the recurrent laryngeal nerve runs in the tracheoesophageal groove and is at risk during mediastinal lymphadenectomy | Speech therapy; if bilateral → may need tracheostomy |
| Vagus nerve injury | Virtually universal | Vagotomy during esophagectomy → delayed gastric emptying [2] | Routine pyloroplasty [2]; prokinetics (metoclopramide, erythromycin) |
| Thoracic duct injury → chylothorax | Diagnosis: increased drain output (milky appearance), TG > 110 or chylomicrons in pleural fluid [2] | Monitor: clinical (SOB), CXR, drain output; diet: NPO + TPN; octreotide; re-operation (suture ligation of thoracic duct stump) if output > 1 L/day [2] | |
| Atelectasis | Common | One-lung ventilation during surgery; pain → splinting → poor cough [2] | Chest physiotherapy, incentive spirometry, early mobilisation |
| Complication | Detail |
|---|---|
| Anastomotic stricture | Requires endoscopic dilation [2]; can be recurrent |
| Post-op GERD | PPI, motility agents [2]; the gastric conduit has no sphincter mechanism |
| Biliary reflux | Bile refluxes into the neo-esophagus; difficult to manage |
| Delayed gastric emptying | Despite pyloroplasty; prokinetics |
| Dumping syndrome | Rapid gastric emptying after vagotomy; early (osmotic) and late (reactive hypoglycaemia) |
| Nutritional deficiencies | Weight loss (nearly universal), iron deficiency, B12 deficiency |
| Absolute Contraindications | Relative Contraindications |
|---|---|
| M1 disease (distant metastasis) | Poor nutritional status (albumin < 30, > 10% weight loss) |
| T4b (unresectable invasion: aorta, trachea, vertebral body) [2] | Advanced age with significant comorbidities |
| Positive peritoneal cytology | FEV1 < 1.25 L (relative — can consider THE approach) [1] |
| Poor performance status (ECOG ≥ 3) | Severe cardiac disease |
| Patient refusal |
High Yield Summary — Management
- T1a (mucosal) → EMR/ESD (endoscopic therapy); organ-preserving; 90% survival.
- T1b (submucosal) → Esophagectomy + LN dissection (20–25% LN metastasis even without visible LN involvement).
- Locally advanced ADC (T2–T4a, N0–N+, M0) → Perioperative FLOT (preferred) or neoadjuvant chemoRT (CROSS) → esophagectomy. Consider FLOT + durvalumab if PD-L1 CPS ≥ 1.
- Locally advanced SCC (T2–T4a, N0–N+, M0) → Neoadjuvant chemoRT (CROSS: paclitaxel/carboplatin + 41.4 Gy) is preferred → esophagectomy.
- Inoperable / unfit → Definitive chemoRT (radical RT is also curative, especially for SCC).
- SCC is more sensitive to chemoRT; ADC is less sensitive → surgery is the backbone for ADC.
- Stage IV (M1) / T4b → Palliative: stenting, endoluminal ablation, RT/brachytherapy, chemotherapy, nutritional support (PEG/jejunostomy).
- Esophagectomy approaches: Ivor-Lewis (2-stage, intrathoracic anastomosis), McKeown (3-stage, cervical anastomosis), Transhiatal (no thoracotomy, limited LN dissection).
- LN dissection is mandatory in ALL approaches; resection margin generous due to submucosal spread.
- Gastric conduit — survives on right gastroepiploic artery; routine pyloroplasty for vagal denervation; feeding jejunostomy.
- Major complications: pneumonia (20%), anastomotic leak (10%), RLN injury (20%), chylothorax, conduit ischaemia.
- Barrett's management: PPI for all; surveillance stratified by dysplasia grade; EMR + RFA for dysplastic Barrett's.
- Adjuvant nivolumab (CheckMate 577) — category 1 after neoadjuvant chemoRT + R0 resection with residual pathologic disease.
- MSI-H/dMMR tumours — consider neoadjuvant immunotherapy (dostarlimab, nivolumab + ipilimumab, pembrolizumab, or tremelimumab + durvalumab).
- FLOT toxicity — ~85% grade 3–4 neutropenia; reserve for fit patients with good PS. CROSS toxicity — radiation esophagitis (up to 84%), leukopenia, post-op pulmonary complications.
Active Recall - Management of CA Esophagus
References
[1] Senior notes: felixlai.md (Esophageal cancer — Treatment sections: General principles, Medical treatment, Surgical treatment, Palliative treatment, Prevention of complications; Barrett's esophagus — Management; Siewert classification) [2] Senior notes: maxim.md (CA esophagus — Management table, Endoscopic therapy, Esophagectomy, Neoadjuvant therapy CROSS, Complications of esophagectomy, Primary chemoRT, Palliative treatments; Barrett's oesophagus — Management) [3] Esophageal and Esophagogastric Junction Cancers. National Comprehensive Cancer Network (NCCN) Guidelines v2.2026. Updated 2026-01-21. [4] Yang H, Wang F, Hallemeier CL, Lerut T, Fu J. Oesophageal Cancer. Lancet. 2024;404(10466):1991-2005. doi:10.1016/S0140-6736(24)02226-8. [5] Kato K, Machida R, Ito Y, et al. Doublet Chemotherapy, Triplet Chemotherapy, or Doublet Chemotherapy Combined With Radiotherapy as Neoadjuvant Treatment for Locally Advanced Oesophageal Cancer (JCOG1109 NExT). Lancet. 2024;404(10447):55-66. doi:10.1016/S0140-6736(24)00745-1. [6] Chen R, Liu Q, Li Q, et al. A Phase II Clinical Trial of Toripalimab Combined With Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (NEOCRTEC1901). EClinicalMedicine. 2023;62:102118. doi:10.1016/j.eclinm.2023.102118. [7] Koyanagi K, Kato K, Ito Y, et al. Impact of preoperative therapy for locally advanced thoracic esophageal cancer on the risk of perioperative complications: Results from multicenter phase III trial JCOG 1109. J Clin Oncol. 2021;39(Suppl 3):162. doi:10.1200/JCO.2021.39.3_suppl.162.
Complications of CA Esophagus
Complications of esophageal cancer fall into two broad categories: (A) complications of the disease itself (the tumour doing damage) and (B) complications of treatment (the price we pay for attempting to cure or palliate it). Both are high-yield and commonly tested.
A. Complications of the Disease (Tumour-Related)
These complications arise directly from the tumour's local invasion, lymphatic/hematogenous spread, and systemic metabolic effects. They follow logically from the anatomy covered in Part 1 — the esophagus sits in the mediastinum surrounded by vital structures, and it has no serosal barrier to slow invasion.
| Feature | Detail |
|---|---|
| Mechanism | The esophagus and trachea/left main bronchus are in direct contact in the upper and mid-thorax. Tumour (usually mid-esophageal SCC) invades through the adventitia into the posterior membranous wall of the trachea or bronchus, creating an abnormal communication — a fistula. Swallowed food and saliva pass directly into the airway. |
| Clinical presentation | Aspiration pneumonia — secondary to formation of tracheobronchial fistula [1]; coughing on swallowing (pathognomonic — Ono's sign); recurrent lower respiratory tract infections; choking; fever |
| Why it matters | TEF is a devastating complication — once established, the patient aspirates with every swallow. Median survival after TEF formation is measured in weeks without intervention. |
| Management | Covered esophageal stent (SEMS) to seal the fistula; covered tracheal/bronchial stent ("double stenting" if needed); palliative RT may help shrink tumour around the fistula; NPO + nutritional support (PEG/jejunostomy); antibiotics for aspiration pneumonia |
Why does TEF occur so readily in esophageal cancer? The posterior wall of the trachea is membranous (no cartilaginous rings posteriorly) — it is the weakest part of the trachea. The esophagus lies directly behind it with only loose adventitial connective tissue between. With no esophageal serosa to slow invasion, the tumour erodes through both walls relatively quickly.
TEF from Radiation — An Iatrogenic Risk
TEF can also be iatrogenic — radiotherapy causes tumour necrosis, and if the tumour is invading the trachea, necrosis of the tumour tissue creates a fistula. This is why bronchoscopy is performed for upper/mid tumours and tracheal stenting may be placed before RT to prevent this complication [2].
| Feature | Detail |
|---|---|
| Mechanism | Tumour (or stent erosion, or post-RT necrosis) invades through the esophageal wall into the aorta or its branches (esophageal arteries, pulmonary arteries). The high-pressure arterial system is then in direct communication with the esophageal lumen. |
| Clinical presentation | Massive bleeding from aorta — secondary to infiltration of tumour into aorta [1]; presents as catastrophic hematemesis; often preceded by a "herald bleed" (small sentinel bleed hours to days before the fatal exsanguination) |
| Prognosis | Almost universally fatal — exsanguination occurs within minutes |
| Management | Resuscitation is often futile; thoracic endovascular aortic repair (TEVAR) has been attempted in rare cases; palliative/supportive care |
Charcot's triad of aortoesophageal fistula (classic but rarely tested): mid-thoracic pain → herald bleed → exsanguinating hematemesis after a symptom-free interval.
| Feature | Detail |
|---|---|
| Mechanism | The left recurrent laryngeal nerve (RLN) loops under the aortic arch and ascends in the tracheoesophageal groove. Mid/upper thoracic esophageal tumours or metastatic mediastinal lymph nodes compress or invade the nerve → ipsilateral vocal cord paralysis → breathy hoarseness. |
| Clinical significance | Hoarseness in a patient with esophageal cancer indicates locally advanced disease — usually T4 or significant nodal disease in the aortopulmonary window. It may preclude curative resection. |
| Consequence | Beyond hoarseness, a paralysed vocal cord cannot close properly during swallowing → aspiration risk (the glottis cannot seal the airway). This compounds the aspiration risk from TEF or regurgitation. |
| Feature | Detail |
|---|---|
| Mechanism | Progressive tumour growth narrows the lumen. Dysphagia appears when ≥ 60–75% of the lumen is obstructed (lumen < 13 mm). As the tumour grows further, even liquids cannot pass. |
| Consequences | Severe weight loss (cancer cachexia amplified by starvation); dehydration → pre-renal AKI; electrolyte derangements (hypokalemia, hyponatremia from vomiting); micronutrient deficiency; immunosuppression → susceptibility to infection |
| Management | Esophageal stenting or dilatation; nutritional support (PEG, jejunostomy, TPN); rehydration |
| Feature | Detail |
|---|---|
| Mechanism | Ulceration of the friable tumour surface → chronic low-grade bleeding (occult) → iron deficiency anemia. Rarely, erosion into a major vessel (aorta, pulmonary artery) → acute catastrophic UGIB (see aortoesophageal fistula above). |
| Presentation | Chronic: pallor, fatigue, microcytic anemia. Acute: hematemesis, melena, hemodynamic instability |
These arise from hematogenous and lymphatic spread:
| Site | Complication | Mechanism |
|---|---|---|
| Liver | Hepatomegaly, jaundice, ascites, liver failure | Metastatic deposits replace hepatic parenchyma; portal vein/hepatic vein involvement |
| Lung | Cough, hemoptysis, dyspnea, pleural effusion | Parenchymal metastases; lymphangitis carcinomatosis; malignant pleural effusion |
| Bone | Pathological fractures, spinal cord compression, hypercalcemia | Osteolytic metastases weaken bone; vertebral collapse can compress the spinal cord |
| Adrenal | Usually asymptomatic; rarely adrenal insufficiency | Bilateral adrenal metastases (uncommon to cause clinical insufficiency) |
| Brain | Headache, seizures, focal neurological deficits | Parenchymal metastases with surrounding edema |
| Syndrome | Mechanism | Histology |
|---|---|---|
| Hypercalcaemia of malignancy (HHM) | PTHrP secretion (10% of SCC) [2] — PTH-related peptide mimics PTH → ↑ osteoclastic bone resorption + ↑ renal calcium reabsorption | SCC predominantly |
| Hypertrophic osteoarthropathy | Periosteal new bone formation in long bones; clubbing; joint pain; mechanism uncertain (VEGF, PDGF release?) | Both histologies |
Hypercalcaemia in Esophageal SCC
Hypercalcaemia: HHM — PTHrP (10%) [2]. If a patient with known esophageal SCC becomes confused, constipated, and polyuric, check the corrected calcium. Hypercalcaemia of malignancy is the most common metabolic emergency in cancer and is treated with aggressive IV hydration + IV zoledronic acid (bisphosphonate) + calcitonin for rapid effect.
B. Complications of Treatment
B1. Complications of Esophagectomy [1][2]
Esophagectomy is one of the highest-morbidity operations in surgery. Understanding complications from first principles requires knowing what gets disturbed during the operation.
| Complication | Incidence | Mechanism (First Principles) | Diagnosis and Management |
|---|---|---|---|
| Pulmonary complications [1] | — | — | — |
| Atelectasis [1] | Very common | One-lung ventilation during surgery [2] collapses the operative lung; post-op pain causes splinting → shallow breathing → mucus plugging → lobar/segmental collapse | CXR: loss of volume, opacification; Rx: chest physiotherapy, encourage coughing, deep breathing, early mobilisation [1] |
| Pneumonia [1] | 20% [2] | Due to smoker status, thoracotomy, one-lung ventilation, vocal cord palsy [2] — all contribute to poor secretion clearance and aspiration risk | Sputum culture; antibiotics; chest physiotherapy |
| Bronchospasm [1] | — | Irritation of airways during one-lung ventilation; pre-existing COPD/asthma | Nebulised bronchodilators |
| ARDS [1] | Rare | Systemic inflammatory response to major surgery; fluid overload; aspiration; sepsis | Ventilatory support in ICU; lung-protective ventilation |
| Pulmonary embolism [1] | — | Venous stasis (prolonged surgery + post-op immobility) + hypercoagulability of malignancy → DVT → PE | CTPA; therapeutic anticoagulation; prophylaxis: LMWH + TED stockings + early mobilisation |
| Respiratory failure [1] | — | Culmination of multiple pulmonary insults (atelectasis + pneumonia + effusion + pain) | Ventilatory support; address underlying cause |
| Cardiac complications [1] | — | — | — |
| Atrial fibrillation (AF) [1] | ~15–25% | Mediastinal dissection irritates the vagus nerve and pericardium; fluid shifts; electrolyte imbalances (hypokalemia, hypomagnesemia); systemic inflammatory response | Rate control (beta-blockers, amiodarone); correct electrolytes; often self-limiting |
| Myocardial infarction [1] | Rare | Demand ischemia (tachycardia + hypotension + anemia in a patient with pre-existing coronary disease) | Troponin, ECG; cardiology input |
| Complication | Incidence | Mechanism (First Principles) | Diagnosis and Management |
|---|---|---|---|
| Anastomotic leak [1][2] | 10% [2] | The anastomosis between the gastric conduit and the remaining esophagus fails to heal. Risk factors: poor blood supply of esophagus, tension of conduit, absence of serosa, use of neoadjuvant RT, surgeon technique [2]. The esophagus lacks serosa → no serosal seal to protect the anastomosis. The conduit's blood supply is tenuous at its tip (furthest from the right gastroepiploic artery). | Patient is usually kept NPO 5–7 days following surgery [1]; gastrografin swallow can be performed to check for leak from day 5–7 before initiating oral intake [1]; Rx: NPO, IV fluids, TPN, antibiotics, monitor drain output [2]; cervical anastomotic leak: lay open wound for drainage (three-stage only) [1][2]; intrathoracic leak: associated with high mortality rate; large or poorly drained leaks require operative exploration [1]; endoscopic: stenting, endoscopic vacuum therapy (EndoSponge) [2] |
| Conduit ischaemia [2] | — | The gastric conduit survives on the right gastroepiploic and right gastric arteries after ligation of left-sided supply. The conduit tip (furthest from the blood supply) is most vulnerable. Complete ischaemia = conduit necrosis — a surgical emergency. | Suspect if sepsis or metabolic acidosis within first 24 hours [2]; prevention: intraoperative ICG (indocyanine green fluorescence angiography) [2]; investigations: CT thorax + abdomen with contrast, OGD [2]; conservative if mild (Types 1/2); take down anastomosis if severe (Type 3): cervical esophagostomy + resection of ischaemic conduit [2] |
| Anastomotic stricture [1][2] | Late | Scar tissue formation at the anastomosis during healing → progressive narrowing → recurrent dysphagia weeks to months post-op | Requires endoscopic dilation [2]; may need multiple sessions; refractory strictures may need temporary stenting |
Why is anastomotic leak the most feared complication? Consider the location:
- Intrathoracic anastomosis (Ivor-Lewis): leak → saliva, gastric contents, and bacteria spill into the mediastinum → mediastinitis → sepsis → multi-organ failure. Mortality 30–50%.
- Cervical anastomosis (McKeown): leak → drains externally through the neck wound → much safer, can be managed by laying the wound open. This is why some surgeons prefer the McKeown approach despite its higher leak rate — the consequences of a leak are far less severe [2].
| Structure Injured | Incidence | Consequence | Management |
|---|---|---|---|
| Recurrent laryngeal nerve (RLN) [1][2] | 20% [2] — during LN dissection | Hoarseness; increased risk of aspiration pneumonia [1] (paralysed vocal cord cannot protect the airway during swallowing) | Speech therapy; medialization thyroplasty if persistent; swallowing precautions |
| Vagus nerve [2] | Virtually universal | Delayed gastric emptying [2] — vagal denervation → loss of coordinated gastric motility → gastroparesis | Routine pyloroplasty is performed at the time of surgery to pre-empt this [2]; post-op prokinetics (metoclopramide, erythromycin) |
| Thoracic duct [1][2] | — | Chylothorax — chyle (lymphatic fluid rich in triglycerides and chylomicrons) leaks into the pleural space | Diagnosis: increase in chest tube output + change from serosanguinous to milky appearance with enteral alimentation [1]; output is not milky initially due to absence of fat ingestion immediately post-operatively [1]; TG > 110 mg/dL or chylomicrons in pleural fluid is diagnostic [1][2]; Rx: NPO + TPN; octreotide; surgical ligation (right thoracotomy + ligation of thoracic duct stump) if output > 1 L/day [1][2] |
| Other organs [2] | Rare | Descending aorta, pulmonary vein, trachea/bronchus, heart — intraoperative injury | Immediate surgical repair |
Chylothorax — Why the Drain Is NOT Milky on Day 1
Output is not milky initially due to absence of fat ingestion immediately post-operatively [1]. The patient is NPO post-operatively and receiving TPN (which goes straight into the bloodstream). Only when enteral feeding is started and dietary fat is absorbed via lacteals → thoracic duct → does the leak become milky. This is why chylothorax may not be recognised until day 2–3 when enteral feeds (via jejunostomy) begin. The key is to watch for a sudden increase in drain output that changes character.
| Complication | Mechanism | Management |
|---|---|---|
| Anastomotic stricture [1][2] | Fibrosis at the anastomosis → progressive dysphagia | Endoscopic dilation [2]; refractory cases may need stenting or surgical revision |
| Post-operative GERD [1][2] | The gastric conduit has no sphincter mechanism; it is essentially an open tube from the neck/thorax to the stomach → free reflux | PPI, motility agents [2]; elevate head of bed; dietary modification |
| Biliary reflux [2] | Bile from the duodenum refluxes into the gastric conduit and upwards — PPI is ineffective because bile reflux is alkaline, not acidic | Sucralfate (mucosal protection); bile acid binders (cholestyramine); prokinetics |
| Delayed gastric emptying [1][2] | Vagotomy (see above) despite pyloroplasty | Prokinetics; dietary modification (small frequent meals); rarely endoscopic pyloric intervention |
| Dumping syndrome | Loss of pyloric regulation (pyloroplasty + vagotomy) → rapid emptying of hyperosmolar content into small bowel → early dumping (fluid shifts → vasomotor symptoms within 30 min of eating) and late dumping (reactive hypoglycaemia 1–3 hours post-meal) | Dietary modification (small, frequent, low-carbohydrate meals); acarbose for late dumping; octreotide for refractory cases |
| Functional disorders [1] | GERD, dysphagia, delayed gastric emptying [1] — all grouped under this umbrella | Multifaceted approach as above |
| Complication | Mechanism |
|---|---|
| RT-induced fibrosis [2] | Radiation damages connective tissue → progressive fibrosis of the mediastinum and esophageal bed months to years later → stricture, dysmotility |
| Worsened dysphagia [2] | Radiation-induced mucosal oedema and inflammation during treatment → transient worsening before improvement; long-term stricture |
| Radiation esophagitis | Acute mucosal inflammation → odynophagia, dysphagia; self-limiting but distressing |
| Iatrogenic TEF | Tumour necrosis from RT in a tumour invading the trachea → fistula formation (see above) |
| Myelosuppression | Chemotherapy (cisplatin, 5-FU) → bone marrow suppression → neutropenia, anemia, thrombocytopenia |
| Nephrotoxicity | Cisplatin is directly nephrotoxic (proximal tubular damage) → aggressive hydration and renal monitoring is mandatory |
| Mucositis | 5-FU and radiation → oral and esophageal mucosal breakdown → pain, infection risk |
| Complication | Mechanism |
|---|---|
| Perforation [1] | Dilation before stent placement or stent expansion forces → esophageal wall rupture |
| Erosion [1] | Stent edges erode into the esophageal or tracheal wall over time → fistula or bleeding |
| Obstruction of tube [1] | Tumour ingrowth through uncovered portions of the stent; food impaction |
| Migration of the stent [1] | Stent moves distally (especially if tumour shrinks with chemoRT); can cause gastric outlet obstruction or small bowel obstruction |
| Reflux | Stent across the EGJ → abolishes sphincter function → intractable GERD |
| Inability to give RT after stenting [2] | Metal stent causes dose inhomogeneity and scatter artefact during radiotherapy planning; also risk of fistula if tumour necroses around the stent |
High Yield Summary — Complications
Disease-related:
- TEF — most feared local complication; coughing on swallowing is pathognomonic; managed with covered SEMS ± tracheal stent.
- Aortoesophageal fistula — almost universally fatal massive hemorrhage; herald bleed precedes exsanguination.
- RLN palsy — hoarseness indicates locally advanced disease (T4/nodal); also increases aspiration risk.
- Hypercalcaemia (PTHrP) — 10% of SCC; confusion, constipation, polyuria; treat with hydration + bisphosphonate.
Esophagectomy (early):
- Pneumonia (20%) — smoker, thoracotomy, one-lung ventilation, RLN palsy.
- Anastomotic leak (10%) — intrathoracic leak = mediastinitis (life-threatening); cervical leak = safer (lay open wound). Check with gastrografin swallow day 5–7.
- Conduit ischaemia — suspect if sepsis/metabolic acidosis within 24 hours; prevent with intraoperative ICG.
- Chylothorax — milky drain output after enteral feeding starts; TG > 110 diagnostic; NPO + TPN + octreotide; surgery if > 1 L/day.
- RLN injury (20%) — during LN dissection.
Esophagectomy (late): Anastomotic stricture (endoscopic dilation), GERD (PPI), biliary reflux, delayed gastric emptying, dumping syndrome.
ChemoRT: RT-induced fibrosis, worsened dysphagia, iatrogenic TEF, myelosuppression, cisplatin nephrotoxicity.
Palliative stenting: Perforation, erosion, migration, obstruction, inability to give subsequent RT.
Active Recall - Complications of CA Esophagus
References
[1] Senior notes: felixlai.md (Esophageal cancer — Prognosis/Complications section, Post-operative complications table, Prevention of complications, Palliative treatment, Chylothorax details) [2] Senior notes: maxim.md (Complications of esophagectomy — Early and Late, Neoadjuvant therapy side effects, Palliative treatments, Clinical features including hypercalcaemia)
High Yield Summary
Definition: Malignant epithelial neoplasm of the esophagus; two main types: SCC (upper 2/3, dominant in Asia/HK ~90%) and ADC (lower 1/3, dominant in West, arising from Barrett's esophagus).
Epidemiology: Male > Female (3:1); peak age 60–70; poor prognosis (5-year survival 5–10%); > 50% have metastases at presentation.
Anatomy: 25 cm tube, no serosa (adventitia only) → early local invasion; rich submucosal lymphatic plexus → early and extensive longitudinal lymphatic spread; 3 anatomical narrowings; drainage varies by region (upper → cervical nodes; middle → mediastinal; lower → celiac/portal).
Risk factors — SCC: Smoking, alcohol, hot drinks, nitrosamines, dietary deficiency (selenium, fruit/veg), betel nut, achalasia, caustic stricture, Plummer-Vinson syndrome, tylosis, H&N cancer history (field cancerization), prior radiation.
Risk factors — ADC: GERD → Barrett's esophagus (metaplasia-dysplasia-carcinoma sequence), obesity, smoking.
Modes of spread: (1) Direct — TE fistula, RLN invasion, aortic invasion; (2) Lymphatic — bidirectional, skip metastases, Virchow's node; (3) Hematogenous — liver, lung, bone, adrenals.
Clinical features: Progressive dysphagia (solids → liquids) + weight loss = classic presentation; late features: odynophagia, hoarseness (RLN), TE fistula (cough on swallowing), hematemesis, supraclavicular lymphadenopathy.
Classifications: Histological (SCC vs ADC); Anatomical (cervical/upper/mid/lower thoracic); TNM (AJCC 8th ed); Siewert (I/II/III for EGJ tumours); Prague (Barrett's).
Field cancerization: Shared carcinogen exposure across upper aerodigestive tract → synchronous/metachronous tumours → always perform panendoscopy.
High Yield Summary — Differential Diagnosis of CA Esophagus
- Progressive dysphagia for solids → liquids = mechanical obstruction until proven otherwise → CA esophagus is the number one concern
- Solids AND liquids from onset = motility disorder (achalasia, DES, scleroderma)
- Intermittent dysphagia with food impaction in a young atopic male = eosinophilic esophagitis
- Pseudoachalasia mimics achalasia but is caused by cardia malignancy — suspect if age > 60, rapid onset, severe weight loss
- Extramural "4Ts": Tumour/LN, Thyroid, Thymus, Thoracic aortic aneurysm
- Always perform OGD + biopsy as the first-line investigation for progressive dysphagia
High Yield Summary — Diagnostics
- Diagnosis = OGD + biopsy — always first-line; document distance from incisors, tumour span, circumferential involvement, whether scope passes through. Biopsy ALL lesions.
- Chromoendoscopy (Lugol's iodine) — highlights SCC/dysplasia as unstained areas (glycogen depletion). NBI enhances mucosal capillary patterns without dye.
- Staging = EUS + CT + PET-CT — EUS for T and N (best); CT for T4 and M (mandatory); PET-CT for M and treatment response.
- EUS: T1a vs T1b is the critical distinction — T1a → endoscopic therapy; T1b → esophagectomy (20–25% chance of LN metastasis).
- T4a (resectable: pleura, pericardium, diaphragm) vs T4b (unresectable: aorta, trachea, spine) — CT is best for this distinction.
- Bronchoscopy — for upper/mid tumours to detect tracheal invasion; may need stenting before RT to prevent iatrogenic TE fistula.
- Diagnostic laparoscopy — for OGJ/adenocarcinoma; only reliable way to detect peritoneal seeding.
- FEV1 < 1.25 L → avoid thoracotomy → consider transhiatal esophagectomy.
- Contrast choice: Barium (best image) → Gastrografin (if perforation risk) → Omnipaque (if aspiration risk).
High Yield Summary — Management
- T1a (mucosal) → EMR/ESD (endoscopic therapy); organ-preserving; 90% survival.
- T1b (submucosal) → Esophagectomy + LN dissection (20–25% LN metastasis even without visible LN involvement).
- Locally advanced ADC (T2–T4a, N0–N+, M0) → Perioperative FLOT (preferred) or neoadjuvant chemoRT (CROSS) → esophagectomy. Consider FLOT + durvalumab if PD-L1 CPS ≥ 1.
- Locally advanced SCC (T2–T4a, N0–N+, M0) → Neoadjuvant chemoRT (CROSS: paclitaxel/carboplatin + 41.4 Gy) is preferred → esophagectomy.
- Inoperable / unfit → Definitive chemoRT (radical RT is also curative, especially for SCC).
- SCC is more sensitive to chemoRT; ADC is less sensitive → surgery is the backbone for ADC.
- Stage IV (M1) / T4b → Palliative: stenting, endoluminal ablation, RT/brachytherapy, chemotherapy, nutritional support (PEG/jejunostomy).
- Esophagectomy approaches: Ivor-Lewis (2-stage, intrathoracic anastomosis), McKeown (3-stage, cervical anastomosis), Transhiatal (no thoracotomy, limited LN dissection).
- LN dissection is mandatory in ALL approaches; resection margin generous due to submucosal spread.
- Gastric conduit — survives on right gastroepiploic artery; routine pyloroplasty for vagal denervation; feeding jejunostomy.
- Major complications: pneumonia (20%), anastomotic leak (10%), RLN injury (20%), chylothorax, conduit ischaemia.
- Barrett's management: PPI for all; surveillance stratified by dysplasia grade; EMR + RFA for dysplastic Barrett's.
- Adjuvant nivolumab (CheckMate 577) — category 1 after neoadjuvant chemoRT + R0 resection with residual pathologic disease.
- MSI-H/dMMR tumours — consider neoadjuvant immunotherapy (dostarlimab, nivolumab + ipilimumab, pembrolizumab, or tremelimumab + durvalumab).
High Yield Summary — Complications
Disease-related:
- TEF — most feared local complication; coughing on swallowing is pathognomonic; managed with covered SEMS ± tracheal stent.
- Aortoesophageal fistula — almost universally fatal massive hemorrhage; herald bleed precedes exsanguination.
- RLN palsy — hoarseness indicates locally advanced disease (T4/nodal); also increases aspiration risk.
- Hypercalcaemia (PTHrP) — 10% of SCC; confusion, constipation, polyuria; treat with hydration + bisphosphonate.
Esophagectomy (early):
- Pneumonia (20%) — smoker, thoracotomy, one-lung ventilation, RLN palsy.
- Anastomotic leak (10%) — intrathoracic leak = mediastinitis (life-threatening); cervical leak = safer (lay open wound). Check with gastrografin swallow day 5–7.
- Conduit ischaemia — suspect if sepsis/metabolic acidosis within 24 hours; prevent with intraoperative ICG.
- Chylothorax — milky drain output after enteral feeding starts; TG > 110 diagnostic; NPO + TPN + octreotide; surgery if > 1 L/day.
- RLN injury (20%) — during LN dissection.
Esophagectomy (late): Anastomotic stricture (endoscopic dilation), GERD (PPI), biliary reflux, delayed gastric emptying, dumping syndrome.
ChemoRT: RT-induced fibrosis, worsened dysphagia, iatrogenic TEF, myelosuppression, cisplatin nephrotoxicity.
Palliative stenting: Perforation, erosion, migration, obstruction, inability to give subsequent RT.
Barrett's Esophagus
Barrett's esophagus is a metaplastic condition in which the normal stratified squamous epithelium of the distal esophagus is replaced by intestinal-type columnar epithelium with goblet cells, typically due to chronic gastroesophageal reflux, and is a premalignant risk factor for esophageal adenocarcinoma.
Ca Stomach
Gastric carcinoma is a malignant neoplasm arising from the epithelial lining of the stomach, most commonly an adenocarcinoma, associated with risk factors such as H. pylori infection, dietary nitrosamines, and chronic atrophic gastritis.